<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Six months therapy for tuberculous meningitis - Jullien, S - 2016 | Cochrane Library</title> <meta content="Six months therapy for tuberculous meningitis - Jullien, S - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012091.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Six months therapy for tuberculous meningitis - Jullien, S - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012091.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012091.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Six months therapy for tuberculous meningitis" name="citation_title"/> <meta content="Sophie Jullien" name="citation_author"/> <meta content="Jigme Dorji Wangchuck National Referral Hospital" name="citation_author_institution"/> <meta content="sophjullien@gmail.com" name="citation_author_email"/> <meta content="Hannah Ryan" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Manish Modi" name="citation_author"/> <meta content="Postgraduate Institute of Medical Education and Research" name="citation_author_institution"/> <meta content="Rohit Bhatia" name="citation_author"/> <meta content="All India Institute of Medical Sciences" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD012091.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/09/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012091.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012091.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012091.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012091.pub2&amp;doi=10.1002/14651858.CD012091.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="eLIOL3Be";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012091\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012091\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","th","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD012091.pub2",title:"Six months therapy for tuberculous meningitis",firstPublishedDate:"Sep 1, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012091.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012091.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012091.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012091.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012091.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012091.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012091.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012091.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012091.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012091.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3480 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012091.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-sec-0131"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-sec-0061"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-sec-0125"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/appendices#CD012091-sec-0135"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Six months therapy for tuberculous meningitis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/information#CD012091-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sophie Jullien</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/information#CD012091-cr-0003">Hannah Ryan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/information#CD012091-cr-0004">Manish Modi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012091.pub2/information#CD012091-cr-0005">Rohit Bhatia</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/information/en#CD012091-sec-0145">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 September 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012091.pub2">https://doi.org/10.1002/14651858.CD012091.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012091-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012091-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012091-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012091-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/th#CD012091-abs-0002">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012091-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012091-abs-0001" lang="en"> <section id="CD012091-sec-0001"> <h3 class="title" id="CD012091-sec-0001">Background</h3> <p>Tuberculous meningitis (TBM) is the main form of tuberculosis that affects the central nervous system and is associated with high rates of death and disability. Most international guidelines recommend longer antituberculous treatment (ATT) regimens for TBM than for pulmonary tuberculosis disease to prevent relapse. However, longer regimens are associated with poor adherence, which could contribute to increased relapse, development of drug resistance, and increased costs to patients and healthcare systems. </p> </section> <section id="CD012091-sec-0002"> <h3 class="title" id="CD012091-sec-0002">Objectives</h3> <p>To compare the effects of short‐course (six months) regimens versus prolonged‐course regimens for people with tuberculous meningitis (TBM). </p> </section> <section id="CD012091-sec-0003"> <h3 class="title" id="CD012091-sec-0003">Search methods</h3> <p>We searched the following databases up to 31 March 2016: the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE; EMBASE; LILACS; INDMED; and the South Asian Database of Controlled Clinical Trials. We searched the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) and ClinicalTrials.gov for ongoing trials. We also checked article reference lists and contacted researchers in the field. </p> </section> <section id="CD012091-sec-0004"> <h3 class="title" id="CD012091-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) and prospective cohort studies of adults and children with TBM treated with antituberculous regimens that included rifampicin for six months or longer than six months. The primary outcome was relapse, and included studies required a minimum of six months follow‐up after completion of treatment. </p> </section> <section id="CD012091-sec-0005"> <h3 class="title" id="CD012091-sec-0005">Data collection and analysis</h3> <p>Two review authors (SJ and HR) independently assessed the literature search results for eligibility, and performed data extraction and 'Risk of bias' assessments of the included studies. We contacted study authors for additional information when necessary. Most data came from single arm cohort studies without a direct comparison so we pooled the findings for each group of cohorts and presented them separately using a complete‐case analysis. When a study reported more than one cohort, the cohorts were analysed separately. We assessed the quality of the evidence narratively, as using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was inappropriate with no direct comparisons between short‐ and prolonged‐course regimens. </p> </section> <section id="CD012091-sec-0006"> <h3 class="title" id="CD012091-sec-0006">Main results</h3> <p>Four RCTs, 13 prospective cohort studies, and one unpublished ongoing cohort study met our inclusion criteria, and included a total of 2098 participants with TBM. None of the included RCTs directly compared six months versus longer regimens, so we analysed all data as individual cohorts to obtain relapse rates in each set of cohorts. </p> <p>We included 20 cohorts reported in 18 studies. One of these was reported separately, leaving 19 cohorts in the main analysis. We included seven cohorts of participants treated for six months with a total of 458 participants. Three studies were conducted in Thailand, two in South Africa, and one each in Ecuador and Papua New Guinea between the 1980s and 2009. We included 12 cohorts of participants treated for longer than six months (ranging from eight to 16 months), with a total of 1423 participants. Four studies were conducted in India, three in Thailand and one each in China, South Africa, Romania, Turkey, and Vietnam, between the late 1970s and 2011. The unpublished ongoing cohort study is conducted in India and included 217 participants. </p> <p>The proportion of participants classified as having stage III disease (severe) was higher in the cohorts treated for six months (33.2% versus 16.9%), but the proportion with known concurrent HIV was higher in the cohorts treated for longer (0/458 versus 122/1423). Although there were variations in the treatment regimens, most cohorts received isoniazid, rifampicin, and pyrazinamide during the intensive phase. </p> <p>Investigators achieved follow‐up beyond 18 months after completing treatment in three out of the seven cohorts treated for six months, and five out of the 12 cohorts treated for eight to 16 months. All studies had potential sources of bias in their estimation of the relapse rate, and comparisons between the cohorts could be confounded. </p> <p>Relapse was an uncommon event across both groups of cohorts (3/369 (0.8%) with six months treatment versus 7/915 (0.8%) with longer), with only one death attributed to relapse in each group. </p> <p>Overall, the proportion of participants who died was higher in the cohorts treated for longer than six months (447/1423 (31.4%) versus 58/458 (12.7%)). However, most deaths occurred during the first six months in both treatment cohorts, which suggested that the difference in death rate was not directly related to duration of ATT but was due to confounding. Clinical cure was higher in the group of cohorts treated for six months (408/458 (89.1%) versus longer than six months (984/1336 (73.7%)), consistent with the observations for deaths. </p> <p>Few participants defaulted from treatment with six months treatment (4/370 (1.1%)) versus longer treatment (8/355 (2.3%)), and adherence was not well reported. </p> </section> <section id="CD012091-sec-0007"> <h3 class="title" id="CD012091-sec-0007">Authors' conclusions</h3> <p>In all cohorts most deaths occurred in the first six months; and relapse was uncommon in all participants irrespective of the regimen. Further inferences are probably inappropriate given this is observational data and confounding is likely. These data are almost all from participants who are HIV‐negative, and thus the inferences will not apply to the efficacy and safety of the six months regimens in HIV‐positive people. Well‐designed RCTs, or large prospective cohort studies, comparing six months with longer treatment regimens with long follow‐up periods established at initiation of ATT are needed to resolve the uncertainty regarding the safety and efficacy of six months regimens for TBM. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012091-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012091-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012091-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012091-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012091-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD012091-abs-0005">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012091-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012091-abs-0004" lang="en"> <h3>Six months therapy for patients with tuberculous meningitis</h3> <p><b>What is tuberculous meningitis and why is the duration of treatment important?</b> </p> <p>Tuberculous meningitis (TBM) is a severe form of tuberculosis, which affects the membranes that cover the brain and spine. It is associated with high rates of death and disability. While there are standardized international recommendations for treating people with pulmonary tuberculosis (tuberculosis of the lungs) for six months with antituberculous therapy, there is a wide range of differing recommendations and practices for treating people with TBM worldwide. Some specialists recommend nine months, 12 months, or even longer treatment for TBM in order to prevent relapse of the disease. Longer regimens have potential disadvantages: they are associated with poor adherence to treatment, which could contribute to increased relapse and development of drug resistance; and increased costs to patients and healthcare systems. </p> <p><b>What the evidence shows</b> </p> <p>This Cochrane review assessed the effects of six‐month regimens for treating people with TBM compared with longer regimens. Cochrane researchers examined the available evidence up to 31 March 2016 and they included 18 studies. None of the included studies directly compared people with TBM treated for six months with people with TBM treated for longer. Two of the included studies analysed two groups of participants treated for six months and longer than six months. Therefore, the review authors included information from seven groups of people treated for six months (458 people), 12 groups of people treated for longer than 6 months (1423 people), and one ongoing study of 217 people which was analysed separately due to methodological concerns. Although the treatment regimens in the included studies varied, most participants received standard first‐line antituberculous drugs, and were followed up for more than a year after the end of treatment. The studies included adults and children with TBM, but few participants were HIV‐positive. </p> <p>Relapse was an uncommon event across both groups of studies, with only one death attributed to relapse in each group. Most deaths occurred during the first six months of treatment in both groups of studies, which showed that treatment duration did not have a direct impact on the risk of death in these studies. There was a higher death rate in participants treated for longer than six months, and this probably reflects the differences between the participants in the two groups of studies. Few participants defaulted from treatment, and adherence was not clearly documented. </p> <p>They found no evidence of high relapse rates in people treated for six months, and relapse was uncommon in all patients irrespective of regimen. There may be differences between the participants treated for six months and longer than six months that could have led to bias (confounding factors), so further research would help determine if shorter regimens are safe. Most of the data were in patients without HIV, and so these inferences do not apply to patients who are HIV‐positive. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012091-sec-0131" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012091-sec-0131"></div> <h3 class="title" id="CD012091-sec-0132">Implications for practice</h3> <section id="CD012091-sec-0132"> <p>Despite potential confounding, there is no evidence of higher relapse in people treated for only six months: relapse was an uncommon event regardless of the duration of treatment, and there was no higher proportion of deaths among those treated for six months. These data are almost all from participants who are HIV‐negative, and thus it is inappropriate to make inferences from these data about the safety and efficacy of the six month regimen to HIV‐positive people. The quality of the evidence is limited by a lack of studies including a direct comparison between six months and more than six months regimens. </p> </section> <h3 class="title" id="CD012091-sec-0133">Implications for research</h3> <section id="CD012091-sec-0133"> <p>Notably, no randomized controlled trials (RCTs) have compared six months standard first‐line ATT with longer regimens, despite the significant uncertainty around best practice and the consequent variations in practice and guidelines. This could be because of resource constraints and competing research priorities, but it might also be due to prevailing perceptions that six months ATT is simply inadequate in this life‐threatening form of TB disease. </p> <p>We originally conducted this review to inform a guideline development process in India on extrapulmonary TB, the Indian Extra‐Pulmonary TB (INDEX‐TB) Guidelines (<a href="./references#CD012091-bbs2-0165" title="INDEX‐TB Guidelines Group. INDEX‐TB Guidelines ‐ Guidelines on Extra‐Pulmonary Tuberculosis for India. INDEX‐TB Guidelines ‐ Guidelines on Extra‐Pulmonary Tuberculosis for India. First Edition. New Delhi: World Health Organization Country Office India, 2016. ">INDEX‐TB 2016</a>). During the guideline development process, several experts commented that they were concerned about the ethics of conducting a RCT that compared six months ATT with longer regimens in people with TBM, citing their experiences of patients treated for six months who have relapsed. They felt it would be unsafe and unethical to randomize patients to receive six months of ATT. </p> <p>The results of this Cochrane review suggest that relapse is an uncommon event whether participants are treated for six months or longer, and so randomization of participants to a six months regimen would not be unethical in a well‐conducted trial. An adequately powered, multicentre RCT conducted in low‐ and middle‐income countries where TB prevalence is high, that compares six versus nine or 12‐month regimens using the same first‐line drugs in standardized doses would help answer this question. Such trials should involve HIV‐positive and HIV‐negative adults and children, and should be powered to allow subgroup analyses between age group, HIV status, nutritional status, and disease severity at presentation. An alternative to conducting an RCT would be to set up large, prospective cohort studies that compare six months and prolonged treatment regimens, where duration of treatment is clearly decided at initiation of ATT. This would have the advantage of more closely reflecting the outcomes that are achievable in everyday practice, rather in the carefully controlled conditions of a trial, and may be more feasible than an RCT. RCTs have the advantage of being better equipped to deal with the problems of confounding and bias in patient selection that we have identified in the studies included in this review than cohort designs. </p> <p>On the other hand, shortening the overall duration of TBM treatment to achieve outcomes at least as good as the 12 months regimens may be possible through different regimens, such as increasing the length of the intensive phase, changing the doses, or the frequency of administration of the first‐line drugs currently used, or adding or substituting second‐line drugs. These different options need to be addressed. Few trials have been conducted evaluating high doses of rifampicin and use of fluoroquinolones for TBM (<a href="./references#CD012091-bbs2-0056" title="HeemskerkAD , BangND , MaiNTH , ChauTTH , PhuNH , LocPP , et al. Intensified antituberculosis therapy in adults with tuberculous meningitis. The New England Journal of Medicine2016;374(2):124‐34. ">Heemskerk 2016</a>; <a href="./references#CD012091-bbs2-0105" title="RuslamiR , GaniemAR , DianS , AprianiL , AchmadTH , van derVenAJ , et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open‐label, randomised controlled phase 2 trial. The Lancet. Infectious Diseases2013;13(1):27‐35. ">Ruslami 2013</a>; <a href="./references#CD012091-bbs2-0135" title="ThwaitesGE , BhavnaniSM , ChauTT , HammelJP , TörökME , VanWartSA , et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrobial Agents and Chemotherapy2011;55(7):3244‐53. ">Thwaites 2011</a>). However, these trials assessed survival as main outcome and did not follow‐up participants after completion of ATT for relapse. Whether these new regimens would allow shortening of the overall treatment duration is unknown. Most research focuses on pulmonary TB. Several trials assessing new regimens are being developed or are in progress (<a href="./references#CD012091-bbs2-0195" title="ZumlaA , ChakayaJ , CentisR , D'AmbrosioL , MwabaP , BatesM , et al. Tuberculosis treatment and management‐an update on treatment regimens, trials, new drugs, and adjunct therapies. The Lancet. Respiratory medicine2015;3(3):220‐34. [DOI: 10.1016/S2213‐2600(15)00063‐6] ">Zumla 2015</a>). For drug‐sensitive pulmonary TB, a systematic review assessed fluoroquinolones as substitute or additional agents in ATT regimens, and concluded that there is insufficient evidence on whether this would reduce death or relapse (<a href="./references#CD012091-bbs2-0193" title="ZiganshinaLE , TitarenkoAF , DaviesGR . Fluoroquinolones for treating tuberculosis (presumed drug‐sensitive). Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD004795.pub4] ">Ziganshina 2013</a>). When extrapolation of results is contemplated from pulmonary TB to TBM, pharmacodynamics of the antituberculous regimen should be taken into account, to ensure adequate effects of antituberculous agents in the site of infection. Analyses on cerebrospinal (CSF) concentrations of drugs may be required. Thus, additional studies are needed to elucidate the role of fluoroquinolones in TBM treatment, and to further address alternative regimens that would allow shortening of the overall length of ATT. </p> <p>Finally, we noted that there was a lack of homogeneity in the included studies when reporting outcomes and follow‐up. Efforts towards using standardized definitions for relapse and default, at least 12 months follow‐up after completing ATT and better reporting on outcomes including adverse events should be encouraged for future studies to facilitate comparability between them and allow meta‐analysis. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012091-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012091-sec-0030"></div> <section id="CD012091-sec-0031"> <h3 class="title" id="CD012091-sec-0031">Description of the condition</h3> <p>Tuberculosis (TB) is caused by infection with one of several mycobacterial species that belong to the <i>Mycobacterium tuberculosis</i> complex. TB is estimated to be the leading infectious cause of death worldwide alongside HIV, and approximately one‐third of the world's population is thought to have latent TB. TB is associated with poverty. Low‐ and middle‐income countries carry the greatest burden of the disease, and more than three‐quarters of cases are reported in South‐East Asia, the Western Pacific, and Africa (<a href="./references#CD012091-bbs2-0190" title="World Health Organization. Global Tuberculosis Report 2015. http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1 (accessed 22 March 2016). ">WHO 2015</a>). Tuberculous meningitis (TBM) is a severe form of TB, which affects the meninges that cover the brain and spine. TBM is the main form of TB that affects the central nervous system (CNS), which accounts for approximately 1% of all cases of active TB, and 5% to 10% of extrapulmonary TB cases (TB involving organs other than the lungs) (<a href="./references#CD012091-bbs2-0182" title="ThwaitesG , FisherM , HemingwayC , ScottG , SolomonT , InnesJ , British Infection Society. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. The Journal of Infection2009;59(3):167‐87. [DOI: 10.1016/j.jinf.2009.06.011] ">Thwaites 2009</a>; <a href="./references#CD012091-bbs2-0184" title="TörökME . Tuberculous meningitis: advances in diagnosis and treatment. British Medical Bulletin2015;113(1):117‐31. [DOI: 10.1093/bmb/Idv003] ">Török 2015</a>). TBM prevalence is higher in populations with high overall TB prevalence. The World Health Organization (WHO) reported 0.8 million new extrapulmonary TB cases worldwide in 2013 out of 5.4 million people with a first episode of TB (<a href="./references#CD012091-bbs2-0189" title="World Health Organization. Global Tuberculosis Report 2014. http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf (accessed 21 September 2015). ">WHO 2014</a>). TBM mainly affects children and immunosuppressed people (<a href="./references#CD012091-bbs2-0173" title="PrincipiN , EspositoS . Diagnosis and therapy of tuberculosis meningitis in children. Tuberculosis2012;92(5):377‐83. [DOI: 10.1016/j.tube.2012.05.011] ">Principi 2012</a>). </p> <p>TBM is a major contributor to the death and disability associated with TB. Death occurs in around 30% of people with TBM and 50% of people who survive TBM suffer from neurological deficits that cause disability despite antituberculous treatment (ATT) (<a href="./references#CD012091-bbs2-0173" title="PrincipiN , EspositoS . Diagnosis and therapy of tuberculosis meningitis in children. Tuberculosis2012;92(5):377‐83. [DOI: 10.1016/j.tube.2012.05.011] ">Principi 2012</a>). Early diagnosis and prompt treatment with ATT and corticosteroids are the main determinants of outcome in TBM (<a href="./references#CD012091-bbs2-0172" title="PrasadK , SinghMB , RyanH . Corticosteroids for managing tuberculous meningitis. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD002244.pub4] ">Prasad 2016</a>; <a href="./references#CD012091-bbs2-0183" title="ThwaitesGE , vanToornR , SchoemanJ . Tuberculosis meningitis: more questions, still too few answers. The Lancet. Neurology2013;12(10):999‐1010. [DOI: 10.1016/S1474‐4422(13)70168‐6] ">Thwaites 2013</a>). </p> <p>TBM is diagnosed clinically by recognition of meningitis together with findings suggestive of <i>M. tuberculosis</i> infection (<a href="./references#CD012091-bbs2-0173" title="PrincipiN , EspositoS . Diagnosis and therapy of tuberculosis meningitis in children. Tuberculosis2012;92(5):377‐83. [DOI: 10.1016/j.tube.2012.05.011] ">Principi 2012</a>). A "bacteriologically confirmed TBM case" implies confirmation of the diagnosis by identification of <i>M. tuberculosis</i> in the person's cerebrospinal fluid (CSF) by microscopy, cell culture, or molecular methods. A case diagnosed as TBM by a health worker without laboratory confirmation is defined as a "clinically diagnosed TBM case" (<a href="./references#CD012091-bbs2-0188" title="World Health Organization. Definitions and reporting framework for tuberculosis ‐ 2013 revision (updated December 2014). http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf (accessed 01 February 2016). ">WHO 2013</a>). The disease severity at presentation is classified into three stages according to the British Medical Research Council (MRC) (<a href="./references#CD012091-bbs2-0170" title="Medical Research Council. Streptomycin treatment of tuberculous meningitis. The Lancet1948;1(6503):582‐96. ">MRC 1948</a>), based on the Glasgow Coma Scale (GCS) (<a href="./references#CD012091-bbs2-0180" title="TeasdaleG , JennettB . Assessment of coma and impaired consciousness. A practical scale. The Lancet1974;2(7872):81‐4. ">Teasdale 1974</a>) and neurological signs. </p> <p> <ul id="CD012091-list-0001"> <li> <p>Stage I: non‐specific signs and symptoms but no neurological focal signs and GCS of 15. </p> </li> <li> <p>Stage II: minor neurological focal signs such as cranial nerve palsies or GCS of 11 to 14. </p> </li> <li> <p>Stage III: severe neurological deficits such as paresis or GCS equal to or less than 10. </p> </li> </ul> </p> <p>Such classification facilitates comparison between findings from different studies and is useful to predict prognosis. </p> </section> <section id="CD012091-sec-0032"> <h3 class="title" id="CD012091-sec-0032">Description of the intervention</h3> <p>Without treatment, TBM leads to death. To effectively treat people with TBM, ATT must eliminate active TB bacilli to prevent neurological sequelae and death, eliminate dormant bacilli to prevent relapse, and prevent the emergence of drug resistance (<a href="./references#CD012091-bbs2-0191" title="WoodfieldJ , ArgentA . Evidence behind the WHO guidelines: hospital care for children: what is the most appropriate anti‐microbial treatment for tuberculous meningitis?. Journal of Tropical Pediatrics2008;54(4):220‐4. [DOI: 10.1093/tropej/fmn063] ">Woodfield 2008</a>). In contrast to pulmonary TB, there are no standardized international recommendations for treating people with TBM. There is a wide range of differing recommendations and practices for treating people with TBM worldwide (<a href="./appendices#CD012091-sec-0136">Appendix 1</a>). This is partly due to the limited existing evidence regarding the optimal choice and dose of antituberculous drugs, as well as the most appropriate duration of treatment for people with TBM. Most data on treating TBM have been extrapolated from pulmonary TB (<a href="./references#CD012091-bbs2-0163" title="HeemskerkD , DayJ , ChauTTH , DungNH , YenNTB , BangND , et al. Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM‐IT): protocol for a randomized controlled trial. Trials2011;12:25. ">Heemskerk 2011</a>). </p> <p>Regarding treatment duration, two main concerns have led to the perception that treatment longer than the six months regimen for pulmonary TB is needed for people with TBM to ensure microbiological cure and prevent relapse. Firstly, the blood‐brain barrier hinders the penetration of antituberculous drugs to reach adequate drug concentration in the infected site, meaning that it may take longer to eradicate viable bacilli in the person's CNS (<a href="./references#CD012091-bbs2-0183" title="ThwaitesGE , vanToornR , SchoemanJ . Tuberculosis meningitis: more questions, still too few answers. The Lancet. Neurology2013;12(10):999‐1010. [DOI: 10.1016/S1474‐4422(13)70168‐6] ">Thwaites 2013</a>). The second argument concerns relapse rates. In 2013, 0.3 million cases of TB relapse after previous cure of the disease were reported (<a href="./references#CD012091-bbs2-0189" title="World Health Organization. Global Tuberculosis Report 2014. http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf (accessed 21 September 2015). ">WHO 2014</a>). Although relapse rates of 5% are generally considered acceptable for pulmonary TB regimens, this may not be the case for TBM, in which relapse can lead to severe neurodisability and death (<a href="./references#CD012091-bbs2-0158" title="DonaldPR . The chemotherapy of tuberculosis meningitis in children and adults. Tuberculosis2010;90(6):375‐92. [DOI: 10.1016/j.tube.2010.07.003] ">Donald 2010a</a>). Furthermore, reliable parameters for monitoring response to treatment in TBM are lacking, in contrast to pulmonary TB where sputum microscopy and culture are used. Consequently, some specialists recommend 12 months treatment for drug‐sensitive TBM, consisting of a two months intensive phase with isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by a 10 months continuation phase with isoniazid and rifampicin (<a href="./references#CD012091-bbs2-0184" title="TörökME . Tuberculous meningitis: advances in diagnosis and treatment. British Medical Bulletin2015;113(1):117‐31. [DOI: 10.1093/bmb/Idv003] ">Török 2015</a>). </p> <p>All international guidelines, including the WHO guidelines (<a href="./references#CD012091-bbs2-0186" title="World Health Organization. Treatment of tuberculosis guidelines. 4th edition, 2010. http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf?ua=1&amp;ua=1 (accessed 15 May 2015). ">WHO 2010a</a>), recommend the use of isoniazid, rifampicin, and pyrazinamide, usually with a fourth drug such as ethambutol or streptomycin, as first‐line antituberculous drugs in people with TBM. Isoniazid is highly active against rapidly replicating mycobacteria and has good CSF penetration. Rifampicin kills both rapidly replicating and slow or non‐replicating bacilli, while pyrazinamide has strong bactericidal effect against intracellular mycobacteria. Thus, both rifampicin and pyrazinamide are critical drugs to sterilize lesions by killing dormant bacteria and those in remote sites such as the CSF, which is essential to reduce the risk of relapse (<a href="./references#CD012091-bbs2-0159" title="DonaldPR . Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis2010;90(5):279‐92. [DOI: 10.1016/j.tube.2010.07.002] ">Donald 2010b</a>; <a href="./references#CD012091-bbs2-0181" title="ThwaitesGE , HienTT . Tuberculous meningitis: many questions, too few answers. The Lancet. Neurology2005;4(3):160‐70. ">Thwaites 2005a</a>). The introduction of rifampicin allowed the shortening of pulmonary TB treatment (<a href="./references#CD012091-bbs2-0194" title="ZumlaAI , GillespieSH , HoelscherM , PhilipsPPJ , ColeST , AbubakarI , et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. The Lancet. Infectious Diseases2014;14(4):327‐40. [DOI: 10.1016/S1473‐3099(13)70328‐1] ">Zumla 2014</a>). Although rifampicin has poor CSF penetration, its importance in TBM treatment has being emphasized in a trial in which mortality rate was higher among participants with rifampicin‐resistant TBM (<a href="./references#CD012091-bbs2-0132" title="ThwaitesGE , LanNT , DungNH , QuyHT , OanhDT , ThoaNT , et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. The Journal of Infectious Diseases2005;192(1):79‐88. ">Thwaites 2005b</a>). </p> </section> <section id="CD012091-sec-0033"> <h3 class="title" id="CD012091-sec-0033">How the intervention might work</h3> <p>There is uncertainty about the effectiveness of short‐course regimens of six months ATT in people with TBM. Some study authors report that six months were adequate for treating TBM (<a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a>; <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>), while prolonged regimens have disadvantages. Prolonged regimens may increase the risk of drug‐related adverse events and are associated with poor adherence to treatment and default. Poor adherence increases the risk of relapse leading to potential neurological disability and death, and facilitates the development of drug‐resistant bacterial strains (<a href="./references#CD012091-bbs2-0185" title="vanLoenhout‐RooyackersJH , KeyserA , LaheijRJF , VerbeekALM , van derMeerJWM . Tuberculosis meningitis: is a 6‐month treatment regimen sufficient?. International Journal of Tuberculosis and Lung Disease2001;5(11):1028‐35. ">van Loenhout‐Rooyackers 2001</a>). Finally, long regimens lead to greater expenditure of resources and greater workload for TB control programmes. Short‐course regimens may not be long enough to eliminate dormant bacilli from the CNS, and may lead to higher relapse rates. Higher relapse rates may increase neurodisability and death after completion of ATT (<a href="#CD012091-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012091-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Possible disadvantages of prolonged and short‐course antituberculous regimens for treating people with TBM." data-id="CD012091-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/image_n/nCD012091-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Possible disadvantages of prolonged and short‐course antituberculous regimens for treating people with TBM. </p> </div> </div> </div> <p>Relapse is the most daunting possible consequence of using short treatment regimens. There is uncertainty around the lag time between completion of treatment and relapse. However, most relapses seem to occur within the first six months after completing ATT (<a href="./references#CD012091-bbs2-0167" title="JullienS . Length of treatment for TB meningitis: from evidence to recommendation in India [Master dissertation]. Liverpool, UK: Liverpool School of Tropical Medicine, 2015. ">Jullien 2015</a>). Thus, at least six months of follow‐up are required to adequately assess this outcome, and longer follow‐up periods are desirable for detecting all cases of relapse. Defaulters may be at increased risk of relapse due to inadequate dosing with ATT, particularly during the intensive phase of treatment, although direct evidence for this association is lacking in people with TBM (<a href="./references#CD012091-bbs2-0155" title="CondeMB , EfronA , LoredoC , Muzy de SouzaGR , GraçaNP , CezarMC , et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double‐blind, randomised, controlled phase II trial. The Lancet2009;373(9670):1183‐9. [DOI: 10.1016/S0140‐6736(09)60333‐0] ">Conde 2009</a>). The number of deaths and neurological deficits are reduced by early diagnosis and prompt ATT. Indeed, most of the deaths associated with TBM will occur during the first weeks of disease (<a href="./references#CD012091-bbs2-0192" title="YaramişA , GurkanF , ElevliM , SökerM , HaspolatK , KirbaşG , et al. Central nervous system tuberculosis in children: a review of 214 cases. Pediatrics1998;102(5):E49. ">Yaramiş 1998</a>). In preliminary work for this Cochrane Review, <a href="./references#CD012091-bbs2-0167" title="JullienS . Length of treatment for TB meningitis: from evidence to recommendation in India [Master dissertation]. Liverpool, UK: Liverpool School of Tropical Medicine, 2015. ">Jullien 2015</a> attributed deaths occurring after six months of treatment mainly to complications of TBM and comorbidity, such as secondary infection. Few deaths were associated with relapse. Finally, longer regimens expose patients to the risk of adverse effects of antituberculous drugs for longer. </p> </section> <section id="CD012091-sec-0034"> <h3 class="title" id="CD012091-sec-0034">Why it is important to do this review</h3> <p>The most appropriate duration of treatment for people with TBM is uncertain. Although several studies have reported safe outcomes in adults and children with TBM treated with six months regimens (<a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a>; <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>), there are concerns about whether six months regimens would be sufficient to sterilize CSF and thus prevent relapse. Most international guidelines recommend prolonged‐course ATT of nine to 12 months for people with drug‐sensitive TBM. In practice, more than four antituberculous drugs are sometimes used, and regimens may be prolonged up to 24 months for fear of relapse. Treatment is also prolonged in people for whom supervision and follow‐up are doubtful (<a href="./references#CD012091-bbs2-0173" title="PrincipiN , EspositoS . Diagnosis and therapy of tuberculosis meningitis in children. Tuberculosis2012;92(5):377‐83. [DOI: 10.1016/j.tube.2012.05.011] ">Principi 2012</a>). On the one hand, TBM treatment duration must be long enough to eliminate dormant bacilli to prevent relapse. On the other hand, treatment should be as short as possible to avoid disadvantages related to prolonged regimens. Reducing the duration of TBM therapy from prolonged‐course regimens to short‐course regimens could have several benefits, including reduced drug toxicity and improved adherence to treatment, with fewer consequent relapses and lower risk of developing drug‐resistant strains. Additionally, short‐course regimens would reduce the use of resources and workloads in TB control programmes, which are often overburdened in settings where TB incidence is high (<a href="./references#CD012091-bbs2-0155" title="CondeMB , EfronA , LoredoC , Muzy de SouzaGR , GraçaNP , CezarMC , et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double‐blind, randomised, controlled phase II trial. The Lancet2009;373(9670):1183‐9. [DOI: 10.1016/S0140‐6736(09)60333‐0] ">Conde 2009</a>; <a href="./references#CD012091-bbs2-0185" title="vanLoenhout‐RooyackersJH , KeyserA , LaheijRJF , VerbeekALM , van derMeerJWM . Tuberculosis meningitis: is a 6‐month treatment regimen sufficient?. International Journal of Tuberculosis and Lung Disease2001;5(11):1028‐35. ">van Loenhout‐Rooyackers 2001</a>). </p> <p>A study that reviewed treatment duration for people with TBM by comparing case series of adults and children, showed similar completion and relapse rates between six months regimens including at least isoniazid, rifampicin, and pyrazinamide and longer regimens (<a href="./references#CD012091-bbs2-0185" title="vanLoenhout‐RooyackersJH , KeyserA , LaheijRJF , VerbeekALM , van derMeerJWM . Tuberculosis meningitis: is a 6‐month treatment regimen sufficient?. International Journal of Tuberculosis and Lung Disease2001;5(11):1028‐35. ">van Loenhout‐Rooyackers 2001</a>). In this review, we have included more recent studies, and performed 'Risk of bias' assessments and appraised the quality of the evidence. </p> <p>This review was prompted as part of work with the Central TB Division, Ministry of Health and Family Welfare in India, and the All India Institute of Medical Sciences in New Delhi in preparation for the Indian Extra‐Pulmonary TB (INDEX‐TB) guidelines (<a href="./references#CD012091-bbs2-0165" title="INDEX‐TB Guidelines Group. INDEX‐TB Guidelines ‐ Guidelines on Extra‐Pulmonary Tuberculosis for India. INDEX‐TB Guidelines ‐ Guidelines on Extra‐Pulmonary Tuberculosis for India. First Edition. New Delhi: World Health Organization Country Office India, 2016. ">INDEX‐TB 2016</a>). There was uncertainty and debate as to whether six to nine months of treatment is as safe as longer regimens for treating people with TBM (<a href="./references#CD012091-bbs2-0167" title="JullienS . Length of treatment for TB meningitis: from evidence to recommendation in India [Master dissertation]. Liverpool, UK: Liverpool School of Tropical Medicine, 2015. ">Jullien 2015</a>), with varying views on what the literature showed. As we knew there were no randomized controlled trials (RCTs), we sought to summarize and critically appraise evidence from observational studies. The initial systematic review found several observational studies that reported low numbers of relapse with short regimens, but did not include all the available evidence for longer regimens. In this Cochrane Review, we examined the effects of six months (short‐course) and longer than six months (prolonged‐course) regimens on TBM outcomes. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012091-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012091-sec-0035"></div> <p>To compare the effects of short‐course (six months) regimens versus prolonged‐course regimens for people with tuberculous meningitis (TBM). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012091-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012091-sec-0036"></div> <section id="CD012091-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012091-sec-0038"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs), quasi‐RCTs, and prospective cohort studies. As our preliminary work (<a href="./references#CD012091-bbs2-0167" title="JullienS . Length of treatment for TB meningitis: from evidence to recommendation in India [Master dissertation]. Liverpool, UK: Liverpool School of Tropical Medicine, 2015. ">Jullien 2015</a>) suggested a lack of studies that directly compared short‐course and prolonged‐course treatment, we included prospective cohort studies in which all participants were treated with the same duration of antituberculous treatment (ATT). </p> </section> <section id="CD012091-sec-0039"> <h4 class="title">Types of participants</h4> <p>Adults and children with a diagnosis of presumed drug sensitive tuberculous meningitis (TBM) as defined by the study authors, from all settings and countries. </p> </section> <section id="CD012091-sec-0040"> <h4 class="title">Types of interventions</h4> <section id="CD012091-sec-0041"> <h5 class="title">Short‐course regimens</h5> <p>ATT regimens of six months that included rifampicin.</p> </section> <section id="CD012091-sec-0042"> <h5 class="title">Prolonged‐course regimens</h5> <p>ATT regimens of more than six months that included rifampicin.</p> </section> </section> <section id="CD012091-sec-0043"> <h4 class="title">Types of outcome measures</h4> <section id="CD012091-sec-0044"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012091-list-0002"> <li> <p>Relapse: the number of participants in each treatment group who had new symptoms and signs of TBM after resolution of disease and completion of ATT. We included studies with a minimum of six months follow‐up after completion of ATT<sup>a</sup>. </p> </li> </ul> </p> </section> <section id="CD012091-sec-0045"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012091-list-0003"> <li> <p>Death from any cause.</p> </li> <li> <p>Death after six months of ATT. We were interested in this outcome in order to discriminate the number of deaths that may have been related to duration of treatment. </p> </li> <li> <p>Clinical cure: the number of participants in each treatment group who completed treatment according to the original treatment plan without evidence of treatment failure at the end of treatment (<a href="./references#CD012091-bbs2-0188" title="World Health Organization. Definitions and reporting framework for tuberculosis ‐ 2013 revision (updated December 2014). http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf (accessed 01 February 2016). ">WHO 2013</a>)<sup>b</sup>. </p> </li> <li> <p>Default: the number of participants in each treatment group who discontinued ATT before the end of treatment, or participants whose treatment was interrupted for eight weeks or more consecutively (<a href="./references#CD012091-bbs2-0188" title="World Health Organization. Definitions and reporting framework for tuberculosis ‐ 2013 revision (updated December 2014). http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf (accessed 01 February 2016). ">WHO 2013</a>). </p> </li> <li> <p>Poor adherence: the number of participants in each treatment group who did not adhere to the prescribed treatment regimen, as reported by study authors, but who did not meet the definition of default given above. </p> </li> </ul> </p> <p><sup>a</sup>Long follow‐up periods are required to reliably detect all cases of relapse. We chose to include studies with a minimum of six months follow‐up as we considered studies with shorter follow‐up periods would be likely to miss cases of relapse.<br/> <sup>b</sup>The World Health Organization (WHO)'s definitions for TB outcomes are primarily based on the assessment of pulmonary TB patients, so sputum smear and culture status are important factors in defining outcomes. Generally, repeating cerebrospinal fluid (CSF) sampling and culture at the end of ATT in TBM participants is not done routinely, therefore CSF smear/culture status is not part of the definition of cure or successful treatment in practice. Our definition of 'clinical cure' is broadly equivalent to the definition of 'treatment completed' in the WHO's nomenclature. </p> <p>We considered the outcomes for this Cochrane Review carefully. Although treatment failure is an important outcome in TBM, there is currently no accepted definition of TBM treatment failure. In this review, we defined treatment failure as referring to participants who failed to improve with ATT, or deteriorated following initial improvement while on ATT. Importantly, this definition excluded participants who deteriorate after completing ATT; we classified these participants as relapses for the purposes of this review. In our preliminary work for the TB‐INDEX guidelines, we included treatment failure as a secondary outcome (<a href="./references#CD012091-bbs2-0165" title="INDEX‐TB Guidelines Group. INDEX‐TB Guidelines ‐ Guidelines on Extra‐Pulmonary Tuberculosis for India. INDEX‐TB Guidelines ‐ Guidelines on Extra‐Pulmonary Tuberculosis for India. First Edition. New Delhi: World Health Organization Country Office India, 2016. ">INDEX‐TB 2016</a>; <a href="./references#CD012091-bbs2-0167" title="JullienS . Length of treatment for TB meningitis: from evidence to recommendation in India [Master dissertation]. Liverpool, UK: Liverpool School of Tropical Medicine, 2015. ">Jullien 2015</a>). During this work, it became apparent that this outcome was not directly related to the duration of treatment, as by definition it can occur at any point during ATT. Furthermore, treatment failure was not well defined or described in many of the included studies, was not reported consistently, and participants were described as having treatment failure usually received longer treatment. Thus, we decided not to include treatment failure as a primary or secondary outcome in this review, although we did provide the information in the '<a href="./full#CD012091-sec-0061">Results</a>' section for completeness. </p> <p>For our inclusion criteria, we also considered length of follow‐up carefully. Long follow‐up periods are required to reliably detect all cases of relapse. Therefore, we excluded studies with short follow‐up to limit detection bias, as this could lead to underestimation of the number of relapses, which was the primary outcome of this review. </p> <section id="CD012091-sec-0046"> <h6 class="title">Adverse events</h6> <p> <ul id="CD012091-list-0004"> <li> <p>All adverse effects related to the ATT.</p> </li> <li> <p>Drug toxicity leading to the discontinuation or modification of the treatment regimen</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD012091-sec-0047"> <h3 class="title">Search methods for identification of studies</h3> <p>We attempted to identify all relevant studies regardless of language or publication status (published, unpublished, in press, and ongoing). </p> <section id="CD012091-sec-0048"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases for relevant studies using the search terms and strategy detailed in <a href="./appendices#CD012091-sec-0137">Appendix 2</a>: the Cochrane Infectious Diseases Group (CIDG) Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library issue 3 2016; MEDLINE (Pubmed, 1966 to 31 March 2016); EMBASE (OVID, 1980 to 31 March 2016); LILACS (1982 to 31 March 2016); INDMED (http://indmed.nic.in/, 31 March 2016); and the South Asian Database of Controlled Clinical Trials. We also searched the WHO International Clinical Trials Registry Platform (ICTRP; <a href="http://www.who.int/ictrp/en/" target="_blank">http://www.who.int/ictrp/en/</a>) and ClinicalTrials.gov for ongoing trials (both accessed on 31 March 2016). </p> </section> <section id="CD012091-sec-0049"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of all studies identified by the above methods for other potentially relevant studies. We contacted researchers at the National Institute for Research in Tuberculosis, Chennai, to identify unpublished studies (grey literature). </p> </section> </section> <section id="CD012091-sec-0050"> <h3 class="title" id="CD012091-sec-0050">Data collection and analysis</h3> <section id="CD012091-sec-0051"> <h4 class="title">Selection of studies</h4> <p>Two review authors (SJ and HR) independently screened the titles and abstracts of the studies identified by the literature searches to identify studies that met eligibility criteria, and removed duplicate reports. We retrieved the full‐text articles of the studies we identified as potentially eligible. SJ and HR independently assessed the full‐text articles for study eligibility using an eligibility form based on the predefined inclusion and exclusion criteria, and resolved any disagreements by discussion. Where eligibility was unclear we attempted to contact the study authors for clarification. We excluded studies that did not meet the inclusion criteria and listed them and their reasons for exclusion in the '<a href="./references#CD012091-sec-0152" title="">Characteristics of excluded studies</a>' table. We constructed a study flow diagram to illustrate this process. </p> </section> <section id="CD012091-sec-0052"> <h4 class="title">Data extraction and management</h4> <p>One review author (SJ) piloted the data extraction form on two studies. Based on the results of the pilot, we modified and finalized the data extraction form. Two review authors (SJ and HR) independently extracted data from the included studies according to the agreed data extraction tool. We compared the data extracted by the two review authors to identify any possible errors. We resolved any discrepancies through discussion and by referring to the original articles. We extracted the following data. </p> <p> <ul id="CD012091-list-0005"> <li> <p>Country, when the study was conducted, study design, inclusion and exclusion criteria applied, and the number of participants recruited. </p> </li> <li> <p>Participant characteristics: age, gender, epidemiological data such as known contact with TB patient, duration of symptoms at presentation, clinical severity of the disease according to the British Medical Research Council (MRC) scale, comorbidity (HIV, other immunosuppression disease and other diseases), and diagnostic methods used (for example, CSF testing, neuroimaging, chest X‐ray, purified protein derivative (PPD) skin test) along with number of bacteriologically confirmed and clinically‐diagnosed TBM cases. </p> </li> <li> <p>Intervention data: description of drugs, dose, route of administration in both the intensive and continuation phase, and duration of ATT for both phases. Administration of other drugs or therapeutic procedures. </p> </li> <li> <p>Outcome data.</p> </li> </ul> </p> <p>For the primary outcome we extracted the following data.</p> <p> <ul id="CD012091-list-0006"> <li> <p>Relapse:</p> <ul id="CD012091-list-0007"> <li> <p>number of relapse cases, stratified by age and HIV status, if available;</p> </li> <li> <p>clinical severity of relapse;</p> </li> <li> <p>clinical severity at original diagnosis;</p> </li> <li> <p>method of diagnosing relapse;</p> </li> <li> <p>time between end of treatment and relapse.</p> </li> </ul> </li> </ul> </p> <p>For the secondary outcomes we extracted the following data.</p> <p> <ul id="CD012091-list-0008"> <li> <p>Death from any cause:</p> <ul id="CD012091-list-0009"> <li> <p>number of deaths, stratified by clinical severity, age, HIV status, if available.</p> </li> </ul> </li> <li> <p>Death after six months of ATT treatment:</p> <ul id="CD012091-list-0010"> <li> <p>number of deaths after six months, stratified by clinical severity, age and HIV status if available; </p> </li> <li> <p>time from start of ATT until death;</p> </li> <li> <p>cause of death, if specified.</p> </li> </ul> </li> <li> <p>Clinical cure:</p> <ul id="CD012091-list-0011"> <li> <p>number of cases cured at end of treatment;</p> </li> <li> <p>number of cases cured stratified by clinical severity, age, HIV status if available.</p> </li> </ul> </li> <li> <p>Default:</p> <ul id="CD012091-list-0012"> <li> <p>number of defaulters, stratified by clinical severity, age and HIV status if available;</p> </li> <li> <p>method of monitoring adherence during treatment (clinical history, direct observation, tablet counting). </p> </li> </ul> </li> <li> <p>Poor adherence:</p> <ul id="CD012091-list-0013"> <li> <p>number of participants not receiving prescribed ATT regimen but not meeting the definition of default; </p> </li> <li> <p>method of monitoring adherence during treatment (clinical history, direct observation, tablet counting). </p> </li> </ul> </li> </ul> </p> <p>In addition, we extracted data on treatment failure (number of participants in each treatment group who failed to improve with ATT, or deteriorated following initial improvement while on ATT), on neurological sequelae (number of participants in each treatment group with neurological sequelae as described by the original study authors), and on follow‐up (length of follow‐up after completing ATT, the way participants were followed‐up, and number and characteristics of losses to follow‐up). </p> <p>For each established outcome, we extracted the number of participants assigned and the numbers analysed in each treatment group. For dichotomous outcomes, we extracted the number of participants experiencing the event. For count data outcomes, we extracted the number of events in the intervention and control group. From our preliminary work, we knew that relapse and default are relatively uncommon. Therefore we did not attempt a time‐to‐event analysis for these outcomes as the results are likely to be misleading. </p> <p>For the purposes of analysis in this review, we categorized treatment groups to six months or more than six months based on the duration of treatment they were scheduled to receive. </p> </section> <section id="CD012091-sec-0053"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Based on our preliminary work, we anticipated there would be no studies with a direct comparison between short and prolonged ATT. We treated the included studies as observational cohort studies for the purpose of analysis in our review. The Cochrane 'Risk of bias' assessment tool, <a href="./references#CD012091-bbs2-0164" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>, and the Downs and Black checklist for assessment of methodological quality, <a href="./references#CD012091-bbs2-0160" title="DownsSH , BlackN . The feasibility of creating a checklist for the assessment of the methodological quality both of randomized and non‐randomized studies of health care interventions. Journal of Epidemiology and Community Health1998;52(6):377‐84. [DOI: 10.1136/jech.52.6.377] ">Downs 1998</a>, are inadequate to assess the quality of single‐arm observational cohort studies. Therefore, we devised a 'Risk of bias' assessment tool to appraise the reliability of the outcome data from each study, based on the domains included in the 'Risk Of Bias In Non‐randomized Studies ‐ of Interventions' (ROBINS‐I) tool (<a href="./references#CD012091-bbs2-0178" title="SterneJAC , HigginsJPT , Reeves BC on behalf of the development group for ROBINS‐I. A tool for assessing Risk Of Bias In Non‐randomized Studies of Interventions, Version 7 March 2016. http://www.riskofbias.info (accessed 7 August 2016). ">Sterne 2016</a>), which applies to non‐randomized, observational cohort studies. As no direct comparison is made between cohorts treated with six and more than six months of ATT, we did not assess participant selection and allocation. At least two review authors independently assessed each included study for potential sources of bias that could have affected the reliability of the outcome data, and resolved any discrepancy through discussion. We classified our judgments as either low, high, or unclear risk of bias based on the following criteria. </p> <p> <ul id="CD012091-list-0014"> <li> <p>Detection bias for outcomes that occurred during the follow‐up period, after completing ATT (relapse, death after six months of ATT): </p> <ul id="CD012091-list-0015"> <li> <p>low risk: the study authors attempted to see all participants (for example, by giving them a clinic appointment, a telephone call, or home visit) at least once at 18 months of follow‐up after the end of ATT or beyond; </p> </li> <li> <p>unclear risk: poorly described method of follow‐up, or follow‐up between six and 18 months; </p> </li> <li> <p>high risk: passive follow‐up or follow‐up with for less than six months.</p> </li> </ul> </li> <li> <p>Detection bias for outcomes that occurred during ATT (death, clinical cure, default, adherence to treatment): </p> <ul id="CD012091-list-0016"> <li> <p>low risk: all participants had clear methods of follow‐up during ATT, through regular visits, hospital‐based treatment or Directly Observed Therapy (DOT) programmes; </p> </li> <li> <p>unclear risk: unclear method of follow‐up during ATT;</p> </li> <li> <p>high risk: passive follow‐up, not hospital‐based.</p> </li> </ul> </li> <li> <p>Attrition bias for outcomes occurring during the follow‐up period, after completing ATT (relapse, death after six months of ATT): </p> <ul id="CD012091-list-0017"> <li> <p>low risk: less than 5% of participants lost to follow‐up at the end of the follow‐up period; </p> </li> <li> <p>unclear risk: between 5 and 10% of participants lost to follow‐up at the end of the follow‐up period; </p> </li> <li> <p>high risk: more than 10% of participants lost to follow‐up at the end of the follow‐up period. </p> </li> </ul> </li> <li> <p>Attrition bias for outcomes occurring during ATT (death, clinical cure, default, adherence to treatment): </p> <ul id="CD012091-list-0018"> <li> <p>low risk: less than 5% of participants lost to follow‐up during ATT;</p> </li> <li> <p>unclear risk: between 5 and ‐10% of participants lost to follow‐up during ATT;</p> </li> <li> <p>high risk: more than 10% of participants lost to follow‐up during ATT.</p> </li> </ul> </li> <li> <p>Performance bias for all outcomes: ATT received for longer than planned could reduce the probability of relapse if clinicians gave prolonged ATT to the participants they judged were at higher risk of relapse. Thus we considered: </p> <ul id="CD012091-list-0019"> <li> <p>low risk: less than 5% of participants had duration of treatment prolonged, with reasons given; </p> </li> <li> <p>unclear: between 5 and 10% of participants had duration of treatment prolonged, or no reasons given; </p> </li> <li> <p>high risk: more than 10% of participants had duration of treatment prolonged.</p> </li> </ul> </li> <li> <p>Confounding bias for all outcomes:</p> <ul id="CD012091-list-0020"> <li> <p>factors that may have affected the main outcomes but were unrelated to the duration of treatment, including poor adherence to ATT (which could lead to relapse and treatment failure), and co‐interventions such as steroids and surgical treatment. </p> </li> </ul> </li> </ul> </p> <p>We summarized the results of the assessment for the group of cohorts that received six months ATT and the group of cohorts that received prolonged ATT regimens, in 'Risk of bias' graphs and tables, with supporting evidence from the study reports (and the '<a href="./references#CD012091-sec-0151" title="">Characteristics of included studies</a>' tables). </p> </section> <section id="CD012091-sec-0054"> <h4 class="title">Measures of treatment effect</h4> <p>We stated in our protocol, <a href="./references#CD012091-bbs2-0196" title="JullienS , RyanH , ModiM , BhatiaR . Short‐course versus prolonged‐course antituberculous treatment in tuberculous meningitis. Cochrane Database of Systematic Reviews2016, Issue 2. [DOI: 10.1002/14651858.CD012091] ">Jullien 2016</a>, that we would calculate the risk ratio (RR) for dichotomous outcomes and the rate ratio for count data outcomes, and that we would present the effect estimates with 95% confidence intervals (CIs). This was not possible, as we did not find any trials that directly compared short versus prolonged course regimens. Therefore, we presented the findings separately for each group of cohorts. </p> </section> <section id="CD012091-sec-0055"> <h4 class="title">Dealing with missing data</h4> <p>Where data from the study reports were insufficient, unclear, or missing, we attempted to contact the study authors for additional information. For all included studies, we performed a complete‐case analysis, which means that we only analysed the available data. </p> </section> <section id="CD012091-sec-0056"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical and methodological diversities by looking at the variability in participants, interventions, and risk of bias of the included cohorts. </p> </section> <section id="CD012091-sec-0057"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to construct funnel plots to assess publication bias, but this was not possible as no comparative trials met the inclusion criteria of this review. </p> </section> <section id="CD012091-sec-0058"> <h4 class="title">Data synthesis</h4> <p>Although we planned to conduct meta‐analyses, this was not possible. Instead we synthesized results narratively and in tables. We attempted to assess the quality of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) principles (<a href="./references#CD012091-bbs2-0162" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. ">Guyatt 2011</a>), but this was not possible due to the lack of direct comparison between short‐ and prolonged‐course regimens. Instead, we constructed a modified 'Summary of findings' table to summarize findings of both groups of cohorts, and assessed the quality of the evidence narratively. We used Review Manager (<a href="./references#CD012091-bbs2-0174" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) to gather and synthesise our findings. </p> </section> <section id="CD012091-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We could not conduct formal subgroup analyses. Instead we explored heterogeneity between trials narratively by considering differences between study populations and intervention, such as: age group of participants, clinical severity of the disease at presentation, HIV status, time of the study, and length of follow‐up. </p> </section> <section id="CD012091-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>We did not perform a sensitivity analysis as we were unable to conduct meta‐analyses.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012091-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012091-sec-0061"></div> <section id="CD012091-sec-0062"> <h3 class="title">Description of studies</h3> <section id="CD012091-sec-0063"> <h4 class="title">Results of the search</h4> <p>We conducted the literature search up to the 31 March 2016 and identified 1541 studies. We identified five additional records through other resources. By screening titles, abstracts, and keywords, we selected 154 records and attempted to retrieve the full‐text articles of these studies. By contacting the first author of one of these potentially eligible studies for clarification, we were granted access to the database of an ongoing prospective observational cohort of participants with tuberculous meningitis (TBM), which met our inclusion criteria (<a href="./references#CD012091-bbs2-0002" title="Alvarez‐UriaG , NaikPK , PakamR , BachuL , MiddeM . Natural history and factors associated with early and delayed mortality in HIV‐infected patients treated of tuberculosis under directly observed treatment short‐course strategy: a prospective cohort study in India. Interdisciplinary Perspectives on Infectious Diseases2012;2012:502012. [DOI: 10.1155/2012/502012] ">Alvarez‐Uria 2012</a>; <a href="./references#CD012091-bbs2-0152" title="NCT02454569 . Vicente Ferrer HIV Cohort Study (VFHCS). clinicaltrials.gov/ct2/show/NCT02454569?term=Vicente+Ferrer+HIV+Cohort+Study&amp;rank=1 (first received 15 May 2015). [NCT02454569] ">NCT02454569</a>). Although some of the participants included in our analysis have also been presented in <a href="./references#CD012091-bbs2-0022" title="Alvarez‐UriaG , MiddeM , PakamR , NaikPK . Initial antituberculous regimen with better drug penetration into cerebrospinal fluid reduces mortality in HIV infected patients with tuberculous meningitis: data from an HIV observational cohort study. Tuberculosis Research and Treatment2013;2013:242604. ">Alvarez‐Uria 2013</a> and <a href="./references#CD012091-bbs2-0153" title="Alvarez‐UriaG , PakamR , MiddeM , YallaPS , NaikPK . Adding streptomycin to an intensified regimen for tuberculous meningitis improves survival in HIV‐infected patients. Interdisciplinary Perspectives on Infectious Diseases2015;2015:535134. [DOI: 10.1155/2015/535134] ">Alvarez‐Uria 2015</a>, all the data we present in this review come from the larger database provided by the study author. Overall, 18 studies presented in 21 records met the inclusion criteria of this review (see the '<a href="./references#CD012091-sec-0151" title="">Characteristics of included studies</a>' table). We had insufficient information to decide inclusion or exclusion of 11 studies (see the '<a href="./references#CD012091-sec-0153" title="">Characteristics of studies awaiting classification</a>' table). We presented the reasons for excluding the remaining 122 reports in the '<a href="./references#CD012091-sec-0152" title="">Characteristics of excluded studies</a>' table. We illustrated this process in the study flow diagram (<a href="#CD012091-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD012091-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012091-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/image_n/nCD012091-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012091-sec-0064"> <h4 class="title">Included studies</h4> <p>We included 17 published studies and one unpublished ongoing cohort. Of the published studies, four were randomized controlled trials (RCTs) and 13 were non‐randomized prospective cohort studies. None of the included RCTs compared six months antituberculous treatment (ATT) versus ATT given for more than six months for TBM, so we analysed all as single cohorts. Overall, we identified seven cohorts treated for six months, and 12 cohorts treated for longer than six months. Any comparisons between regimens of six months and regimens of greater than six months are entirely observational. </p> <section id="CD012091-sec-0065"> <h5 class="title">Cohorts treated for six months</h5> <p>See <a href="#CD012091-tbl-0001">Table 1</a> for a full description of the included cohorts. </p> <div class="table" id="CD012091-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of cohort studies that administered six months ATT</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Setting</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b> Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> ATT regimens</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Duration of FU after ATT, in months</b> </p> <p><b> Mean (range)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Centre</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Adults/children</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> HIV status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> MRC stages of the disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ecuador</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 4/28</p> <p>II: 10/28</p> <p>III: 14/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HRZ/4HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(18 to 30)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Papua New Guinea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HRZS/4(HR)<sub>2</sub> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(up to 24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 7/29</p> <p>II: 12/29</p> <p>III: 10/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HRZS/4HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3</p> <p>(4 to 33)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 9/59</p> <p>II: 40/59</p> <p>III: 10/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HRZS/4HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(16 to 45)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 4/95</p> <p>II: 52/95</p> <p>III: 39/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6HRZEth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 8/45</p> <p>II: 25/45</p> <p>III: 12/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HRZS/4HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 6 months: 27/38</p> <p>Less than 6 months: 7/38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐negative or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 22/184<sup>c</sup> </p> <p>II: 98/184</p> <p>III: 84/184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6HRZEth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 24</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment, E: ethambutol; Eth: ethionamide; FU: follow‐up; H: isoniazid; HIV: human immunodeficiency virus; MRC: Medical Research Council; NR: not reported; R: rifampicin; Z: pyrazinamide.<br/> <sup>a</sup>In this prospective cohort study, data are reported for three successive cohorts in the same centre over time. The first cohort received a 12‐month regimen with 2/4 participants receiving rifampicin, the second a 9‐month regimen with all participants receiving rifampicin, and the third received a 6‐month regimen with all participants receiving rifampicin and pyrazinamide.<br/><br/> <sup>b</sup>HIV‐positive children were treated with a 9‐month regimen due to a perceived slower response to treatment.<br/><br/> <sup>c</sup>There were no diaggregated data for clinical severity of the disease between the cohort of HIV‐negative participants receiving 6 months of treatment and the cohort of HIV‐positive participants receiving 9‐month ATT. </p> </div> </div> <section id="CD012091-sec-0066"> <h6 class="title">Setting and time</h6> <p>The seven cohorts were from single tertiary centres in Thailand (<a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a>; <a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a>; <a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a>), South Africa (<a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a>; <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>), Ecuador (<a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a>), and Papua New Guinea (<a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a>). Four studies were conducted in the 1980s (<a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a>; <a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a>; <a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a>; <a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a>), two in the 1990s (<a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a>; <a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a>), and one between 2006 and 2009 (<a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>). </p> </section> <section id="CD012091-sec-0067"> <h6 class="title">Participants</h6> <p>The seven cohorts included 109 adults (three studies) and 349 children (five studies) diagnosed with TBM. Only <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> reported HIV status, and none of the seven cohorts reported data on malnutrition. Six studies used the British Medical Research Council (MRC) criteria to assess clinical severity (<a href="./references#CD012091-bbs2-0170" title="Medical Research Council. Streptomycin treatment of tuberculous meningitis. The Lancet1948;1(6503):582‐96. ">MRC 1948</a>), but only five of them (256 participants) reported disaggregated data: stage I (mild): 30 participants; stage II (moderate): 141 participants; and stage III (severe): 85 participants. </p> </section> <section id="CD012091-sec-0068"> <h6 class="title">ATT regimens</h6> <p>In all seven studies the intensive phase included at least two months of isoniazid, rifampicin, and pyrazinamide. Four studies also gave streptomycin (<a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a>; <a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a>; <a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a>; <a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a>), and two gave ethionamide (<a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a>; <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>). Five studies gave a two months intensive phase with three or four drugs, followed by a four months continuation phase with isoniazid and rifampicin only (<a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a>; <a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a>; <a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a>; <a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a>; <a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a>), while the two cohorts from South Africa gave four drugs for the whole six months (<a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a>; <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>). </p> <p>Drugs were given orally except streptomycin, which was given intramuscularly. There was some variation between studies in the dosages used (see the '<a href="./references#CD012091-sec-0151" title="">Characteristics of included studies</a>' table). Dosages were given as a single daily administration, except in <a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a>, in which antituberculous drugs were given twice weekly during the continuation phase. Drugs were given under Directly Observed Therapy (DOT) in <a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> and under trial conditions in <a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a>. In <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>, half of the participants were hospital‐based during ATT and the other half were home‐based. In the remaining four studies, drugs were self administered under condition of being recruited in a prospective observational cohort with the purpose of describing TBM outcomes (<a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a>; <a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a>; <a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a>; <a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a>). </p> </section> <section id="CD012091-sec-0069"> <h6 class="title">Corticosteroids</h6> <p>Overall, 344 participants from the seven cohorts received corticosteroids. Different regimens were given to either all participants or only to those with moderate and severe presentation of TBM or with neurological complications, or as part of a RCT to assess the use of corticosteroids (<a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a>), during the first four to eight weeks of ATT. </p> </section> <section id="CD012091-sec-0070"> <h6 class="title">Diagnosis: clinical, radiological, and microbiological characteristics</h6> <p>Diagnosis of TBM was based on characteristic clinical features (see <a href="#CD012091-tbl-0002">Table 2</a>), typical cerebrospinal fluid (CSF) findings (elevated cell count with predominance of lymphocytes, low glucose content, and elevation of protein content), and the presence of acid‐fast bacilli in CSF evidenced by microscopy examination or culture (see <a href="#CD012091-tbl-0003">Table 3</a>). Only one cohort reported 5/28 participants with a previous history of TB (<a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a>). Four cohorts reported known contact with an infectious TB patient (<a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a>; <a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a>; <a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a>; <a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a>). The diagnosis of TBM was bacteriologically confirmed in 56 participants and clinically based in 198 participants among the 254 participants with disaggregated data. Only one study reported performing drug sensitivity testing (<a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a>). </p> <div class="table" id="CD012091-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Diagnosis of TBM: clinical and radiological characteristics in cohorts that received six months ATT</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Previous history of TB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Known contact with TB patient</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PPD skin test positive</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuroimaging</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abnormal chest X‐ray</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Done in all participants.</p> <p>Abnormal findings in 19/28.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/38 (≥ 15 mm or ≥ 10 mm with BCG scar)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myelogram in participants with partial spinal block.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CT scan in 18 participants.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/29</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CT scan: abnormal findings in 31/37. Myelogram for participants with paraparesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/95 between 10 mm and 15 mm,</p> <p>84/95 ≥ 15 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CT scan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41/95</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CT scan on admission: bilateral basal ganglia infarction in all 7 cases who died before completing ATT. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Done, NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; BCG: Bacillus Calmette–Guérin; CT: computed tomography; NR: not reported; PPD: purified protein derivative.<br/> <sup>a</sup><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> and <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> also reported cohorts of participants treated for longer than 6 months, but no disaggregated data are provided on clinical features between both cohorts. </p> </div> </div> <div class="table" id="CD012091-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Diagnosis of TBM: microbiological and other diagnostic characteristics in cohorts that received six months ATT</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>CSF</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Other diagnostic methods for TB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Diagnostic classification</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cell count, protein and glucose content</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Positive AFB smear</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Positive culture</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other tests performed in CSF</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bacteriologically confirmed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinically diagnosed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ELISA for BCG antibodies,</p> <p>ADA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteriological analyses of sputum, gastric aspirate, and urine.</p> <p>1 lymph node biopsy, 1 culture from abscess drainage. Autopsy findings.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Done but NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sputum specimens, fasting gastric aspirates, and pleural fluid for microscopy and culture. </p> <p>Lymph node biopsy for histology and culture.</p> <p>Abdominal ultrasound.</p> <p>BCG vaccine scar.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/29</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pyogenic bacterial and fungal culture, latex agglutination test for bacterial and cryptococcal Ag and cytologic study for malignancy; results NR </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 or 6/59<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 or 54/59<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DST</p> <p>Air encephalogram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastric aspirate for microscopy and culture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77/95</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence of a BCG vaccine scar in 28/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCR for MTB in CSF 2 specimens<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Culture of gastric washings: 43/155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168/184</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ADA: adenosine deaminase activity; AFB: acid‐fast bacillus; Ag: antigen; BCG: Bacillus Calmette–Guérin; CSF: cerebrospinal fluid; DST: drug sensitivity tests; ELISA: enzyme‐linked immunosorbent assay; NR: not reported; MTB: <i>Mycobacterium tuberculosis</i>; PCR: polymerase chain reaction; PPD: purified protein derivative.<br/> <sup>a</sup>Unclear whether the specimens with positive stain were also culture positive.<br/> <sup>b</sup><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> and <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> also reported cohorts of participants treated for longer than 6 months, but no disaggregated data are provided on CSF characteristics and diagnosis classification between the cohorts.<br/> <sup>c</sup>The study authors stated that PCR was not done routinely, but did not report how many specimens were tested this way. The 2 positive PCR specimens were also culture positive. </p> </div> </div> </section> </section> <section id="CD012091-sec-0071"> <h5 class="title">Cohorts treated for longer than six months</h5> <p>See <a href="#CD012091-tbl-0004">Table 4</a> for a full description of the included cohorts. </p> <div class="table" id="CD012091-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Description of cohort studies that administered more than six months ATT</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Setting</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b> Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> ATT regimens</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Duration of ATT (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Duration of FU after ATT, in months <br/> Mean (range)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Centre</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Adults/c <br/> hildren</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> HIV status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Severity of the disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Romania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3HRZ/6HR<sub>2</sub> <br/> (19 cases)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3HR/3HR<sub>2</sub>/6H<sub>2</sub> <br/> (25 cases)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre; university hospitals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I: 7/72</p> <p>II: 34/72</p> <p>III: 31/72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HRZS/6HR <br/> (37 cases) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 10</p> <p>(6 to 24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HRZE <br/> (19 cases) </p> <p>HRES <br/> (6 cases) </p> <p>HRZS <br/> (6 cases) </p> <p>HRZES <br/> (3 cases) </p> <p>HRE <br/> (1 case) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 13</p> <p>(4 to 36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HIV positive excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I: 15/43</p> <p>II: 24/43</p> <p>III: 4/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2(HRZS)<sub>3</sub>/7(HR)<sub>3</sub> <br/> (41 cases) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Median 5.2</p> <p>(IQ 3.4 to 9.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2(HREZS)<sub>3</sub>/1(HREZ)<sub>3</sub> /7(HR)<sub>3</sub> (2 cases) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I: 0/8</p> <p>II: 4/8</p> <p>III: 4/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HRS/7HR <br/> (4 cases) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HSE/10HE <br/> (2 cases) </p> <p>2RSE/10RE <br/> (2 cases) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> <p>(Hong Kong)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre; tertiary and secondary hospitals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults and children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 HIV positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 91/166</p> <p>II: 69/166</p> <p>III: 6/166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HRZES</p> <p>(66 cases)</p> <p>HRZE <br/> (63 cases) </p> <p>HRZS <br/> (24 cases) </p> <p>HRZ <br/> (8 cases) </p> <p>HRE <br/> (2 cases) </p> <p>SHRE <br/> (1 case) </p> <p>HZE <br/> (1 case) </p> <p>HR <br/> (1 case) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.53</p> <p>(mean)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 4/28</p> <p>II: 18/28</p> <p>III: 6/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HRZS/7HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.8</p> <p>(12 to 29)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre; tertiary hospitals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 24/180</p> <p>II: 139/180</p> <p>III: 17/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2SHR/4S<sub>2</sub>EH/6EH <br/> (77 cases) </p> <p>2SHRZ/10EH <br/> (29 cases) </p> <p>2R<sub>2</sub> SHZ/10EH <br/> (74 cases) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(42 to 84)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre; tertiary hospitals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 45/215</p> <p>II: 160/215</p> <p>III: 10/215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2SHE(RZ)<sub>3</sub>/7(RH)<sub>2</sub> <br/> (89 cases) </p> <p>2SHE(RZ)<sub>2</sub>/7(RH)<sub>2</sub> <br/> (96 cases) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV positive excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NDD</p> <p>II: NDD</p> <p>III: 21/42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2(HREZ)<sub>3</sub>/7(HR)<sub>3</sub> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vietnam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre; tertiary hospitals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>436 HIV negative</p> <p>98 HIV positive</p> <p>11 unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 176/545</p> <p>II: 247/545</p> <p>III: 122/545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3RHZS/6RHZ <br/> (399 HIV negative) </p> <p>3RHZE/6RHZ <br/> (98 HIV positive) </p> <p>3RHZES/6RHZ <br/> (43 previously treated) </p> <p>HZE <br/> (2 cases) </p> <p>SE <br/> (1 case) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 53.4</p> <p>(IQ 47.4 to 57)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 HIV positive;</p> <p>3 unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 22/184 <sup>c</sup> </p> <p>II: 98/184</p> <p>III: 84/184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9HRZEth<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0018" title="VisudhiphanP , ChiemchanyaS . Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. The Journal of Pediatrics1989;114(5):875‐9. ">Visudhiphan 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 5/51</p> <p>II: 25/51</p> <p>III: 21/51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(18 to 84)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment, E: ethambutol; Eth: ethionamide; FU: follow‐up; H: isoniazid; HIV: human immunodeficiency virus; IQ: interquartile range; MRC: Medical Research Council; NR: not reported; R: rifampicin; Z: pyrazinamide<br/> <sup>a</sup>It is unclear whether streptomycin twice weekly was also administered in both regimens in the first 3 months.<br/> <sup>b</sup>In this prospective cohort study, data are reported for 3 successive cohorts in the same centre over time. The first cohort received a 12‐month regimen with 2/4 participants receiving rifampicin, the second a 9‐month regimen with all participants receiving rifampicin, and the third received a 6‐month regimen with all participants receiving rifampicin and pyrazinamide.<br/><br/> <sup>c</sup>There were no diaggregated data for clinical severity of the disease between the cohort of HIV‐negative participants receiving 6 months of treatment and the cohort of HIV‐positive participants receiving 9‐month ATT.<br/> <sup>d</sup>The 22 HIV‐positive children were treated with a 9‐month regimen due to a perceived slower response to treatment, as well as the 3 children with <i>M. tuberculosis</i> isoniazid‐monoresistance.<br/></p> </div> </div> <section id="CD012091-sec-0072"> <h6 class="title">Setting and time</h6> <p>The 12 cohorts were from different geographical settings: India (<a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a>; <a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a>; <a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a>; <a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a>), Thailand (<a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a>; <a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a>), South Africa (<a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>), China (<a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a>), Ecuador (<a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a>), Romania (<a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a>), Turkey (<a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a>), and Vietnam (<a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a>). <a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a> was conducted in university hospitals, <a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a> was performed in tertiary and secondary hospitals and chest clinics, and the remaining studies were conducted in tertiary hospitals. Five studies were multicentric (<a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a>; <a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a>; <a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a>; <a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a>; <a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a>). The earliest study was started in 1977 (<a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a>), followed by three studies conducted in the 1980s (<a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a>; <a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a>; <a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a>), four in the 1990s (<a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a>; <a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a>; <a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a>; <a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a>), and four between 2001 and 2011 (<a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a>; <a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a>; <a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a>; <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>). </p> </section> <section id="CD012091-sec-0073"> <h6 class="title">Participants</h6> <p>The 12 cohorts included 893 adults (six studies) and 530 children (seven studies) diagnosed with TBM. Three cohorts included 122/736 HIV‐positive people (<a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a>; <a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a>; <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>); <a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> and <a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a> excluded people with HIV, and the remaining seven cohorts did not report the HIV status of the participants. <a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a> and <a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> reported data on severe malnutrition and included 147/395 children with severe malnutrition according to the growth standards from the Indian Council of Medical Research. Eleven studies used the MRC criteria to assess clinical severity, with disaggregated data in nine cohorts: stage I (mild): 371 participants; stage II (moderate): 743 participants; and stage III (severe): 231 participants (<a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a>; <a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a>; <a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a>; <a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a>; <a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a>; <a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a>; <a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a>; <a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a>; <a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a>; <a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a>; <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>). </p> </section> <section id="CD012091-sec-0074"> <h6 class="title">ATT regimens</h6> <p>Twelve cohorts assessed the effects of more than 20 regimens of between eight and 16 months of duration. All of them comprised at least isoniazid and rifampicin (except two participants in <a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a>), with up to five antituberculous drugs. </p> <p>Drugs were given orally except streptomycin, which was given intramuscularly. The cohorts used different drug dosages (see the '<a href="./references#CD012091-sec-0151" title="">Characteristics of included studies</a>). Intermitent regimens (twice or thrice weekly) were administered in three studies throughout the course of treatment (<a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a>; <a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a>; <a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a>), and in two studies during the intensive or continuation phase only (<a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a>; <a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a>). The remaining studies gave single daily doses. In <a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> and <a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a>, drugs were given under DOT; while in <a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a>, <a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a>, and <a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a>, participants received ATT under trial conditions. In <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>, half of the participants were hospital‐based during ATT and the other half were home‐based. In the remaining studies, drugs were self‐administered under the condition of being recruited to a prospective observational cohort with the purpose of describing TBM outcomes. </p> </section> <section id="CD012091-sec-0075"> <h6 class="title">Corticosteroids</h6> <p>All studies considered corticosteroids, except <a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a> in which authors did not report whether participants received corticosteroids or not. Overall, 1001 participants received corticosteroids. Different regimens were given to either all participants or only to those with moderate and severe presentation of TBM or with neurological complications, or as part of RCTs to assess the use of corticosteroids (<a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a>), during the first four to eight weeks of ATT. </p> </section> <section id="CD012091-sec-0076"> <h6 class="title">Diagnosis: clinical, radiological, and microbiological characteristics</h6> <p>Similarly to the cohorts of participants receiving six months of ATT, diagnosis of TBM was based on characteristic clinical features (see <a href="#CD012091-tbl-0005">Table 5</a>), typical CSF findings, and presence of acid‐fast bacilli in CSF evidenced by microscopy examination or culture (see <a href="#CD012091-tbl-0006">Table 6</a>). Three participants out of 72 presented a previous history of TB in <a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a>. Five studies reported known contact with an infectious TB patient (<a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a>; <a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a>; <a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a>; <a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a>; <a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a>). The diagnosis of TBM was bacteriologically confirmed in 470 participants, clinically‐based in 794 participants among the 1264 participants with disaggregated data from eight studies. Four studies performed drug sensitivity testing (<a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a>; <a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a>; <a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a>; <a href="./references#CD012091-bbs2-0018" title="VisudhiphanP , ChiemchanyaS . Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. The Journal of Pediatrics1989;114(5):875‐9. ">Visudhiphan 1989</a>). </p> <div class="table" id="CD012091-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Diagnosis of TBM: clinical and radiological characteristics in cohorts receiving more than six months ATT</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Previous history of TB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Known contact with TB patient</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PPD skin test positive</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuro‐imaging</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abnormal chest X‐ray</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR (although 1 intracerebral tuberculoma is reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR (although 22 PTB are reported)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Done in all participants.</p> <p>5 tuberculoma,</p> <p>9 hydrocephalus, 14 arteritis, 3 spinal arachnoiditis.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50/166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50/155 had meningeal enhancement, ventricular dilatation, tuberculoma or space occupying lesion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63/158</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CT scan in 21 participants with increased intracranial pressure:</p> <p>10 communicating hydrocephalus</p> <p>3 diffuse cerebral oedema with small lateral ventricles</p> <p>1 associated tuberculoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90/180 (≥10mm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99/180</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137/215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73/215 (≥10mm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CT scans to 68 participants with suspected hydrocephalus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111/215</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CT scan in 30 participants (14 with multiple lacunar infarct, hydrocephalus, basal meningeal enhancement). </p> <p>MRI performed in 11 participants.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active non‐miliary TB: 214/545</p> <p>Miliary TB: 155/545</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CT scan on admission: bilateral basal ganglia infarction in all 7 cases who died before completing ATT. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Done, NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0018" title="VisudhiphanP , ChiemchanyaS . Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. The Journal of Pediatrics1989;114(5):875‐9. ">Visudhiphan 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; CT: computed tomography; MRI: magnetic resonance imaging; NR: not reported; PPD: purified protein derivative; PTB: pulmonary tuberculosis.<br/> <sup>a</sup><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> and <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> also reported cohorts of participants treated for 6 months, but did not provide disaggregated data on clinical features between both cohorts. </p> </div> </div> <div class="table" id="CD012091-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Diagnosis of TBM: microbiological and other diagnostic characteristics in cohorts receiving more than six months ATT</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>CSF</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Other diagnostic methods for TB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Diagnostic classification</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cell count, protein and glucose content</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Positive AFB smear</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Positive culture</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other tests performed in CSF</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bacteriologically confirmed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinically diagnosed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCR: 2/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal ultrasound, sputum smear microscopy. Findings not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41/43</p> <p>23 probable,</p> <p>18 possible</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence of a BCG vaccine scar in 28/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82/166 had AFB smear or culture positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68/166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68/166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98/166</p> <p>14 presumptive, 84 probable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discharge of otitis media with AFB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97/180</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74/215<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88/215<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101/215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114/215</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADA in 29 cases; PCR in 2 samples</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Histology of 2 axillary lymph nodes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65/545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166/545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>187 positive cultures of samples other than CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>187/545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352/545</p> <p>261 probable, 91 possible</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCR for MTB in CSF 2 specimens<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Culture of gastric washings: 43/155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168/184</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0018" title="VisudhiphanP , ChiemchanyaS . Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. The Journal of Pediatrics1989;114(5):875‐9. ">Visudhiphan 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/51</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ADA: adenosine deaminase activity; AFB: acid‐fast bacillus; BCG: Bacillus Calmette–Guérin; CSF: cerebrospinal fluid; DST: drug sensitivity tests; NDD: no disaggregated data; NR: not reported; MTB: <i>Mycobacterium tuberculosis</i>; PCR: polymerase chain reaction; PPD: purified protein derivative; TBM: tuberculous meningitis.<br/> <sup>a</sup>There were 30 positive cultures among 60 participants with severe forms of TB, with no disaggregated data for the 44 TBM cases.<br/> <sup>b</sup><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> and <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> also reported cohorts of participants treated for 6 months, but did not provide disaggregated data on CSF characteristics and diagnosis classification between the cohorts.<br/> <sup>c</sup>Numbers of smear‐ and culture‐positive participants seem to be incorrectly reported.<br/> <sup>d</sup>The study authors stated that PCR was not done routinely, but did not report how many specimens were tested this way. The 2 positive PCR specimens were also culture positive. </p> </div> </div> </section> </section> <section id="CD012091-sec-0077"> <h5 class="title">Outcomes</h5> <p>Although some studies used different definitions of relapse, default, clinical cure, and poor adherence, we collected and presented the data according to the definitions we established in our protocol, <a href="./references#CD012091-bbs2-0196" title="JullienS , RyanH , ModiM , BhatiaR . Short‐course versus prolonged‐course antituberculous treatment in tuberculous meningitis. Cochrane Database of Systematic Reviews2016, Issue 2. [DOI: 10.1002/14651858.CD012091] ">Jullien 2016</a> (see the '<a href="#CD012091-sec-0043">Types of outcome measures</a>' section). </p> <section id="CD012091-sec-0078"> <h6 class="title">Primary outcome</h6> <p>All included studies reported relapse.</p> </section> <section id="CD012091-sec-0079"> <h6 class="title">Secondary outcomes and adverse events</h6> <p>All studies reported death from any cause and clinical cure. We were able to extract data on death after six months of ATT in all the cohorts receiving six months of ATT and in eight cohorts receiving prolonged ATT. We extracted data on default in five and six cohorts of participants treated for six months and more than six months respectively. One cohort study of six months ATT and two cohort studies of more than six months ATT reported poor adherence. </p> <p>Authors of the included studies did not report adverse events uniformly. Some studies collected all adverse events while some others reported only the cases requiring discontinuation of ATT due to drug toxicity, or adverse effects secondary to corticosteroids. Overall, 13 studies reported adverse events related to ATT, and 14 studies reported drug toxicity leading to the discontinuation or modification of the treatment regimen. </p> </section> </section> <section id="CD012091-sec-0080"> <h5 class="title">Additional cohort</h5> <p>All participants in the <a href="./references#CD012091-bbs2-0002" title="Alvarez‐UriaG , NaikPK , PakamR , BachuL , MiddeM . Natural history and factors associated with early and delayed mortality in HIV‐infected patients treated of tuberculosis under directly observed treatment short‐course strategy: a prospective cohort study in India. Interdisciplinary Perspectives on Infectious Diseases2012;2012:502012. [DOI: 10.1155/2012/502012] ">Alvarez‐Uria 2012</a> cohort come from the Vicente Ferrer HIV Cohort Study (VFHCS), which is an ongoing long‐term prospective cohort study of all HIV‐positive patients who have attended Rural Development Trust (RDT) hospitals in the district of Anantapur, India (<a href="./references#CD012091-bbs2-0152" title="NCT02454569 . Vicente Ferrer HIV Cohort Study (VFHCS). clinicaltrials.gov/ct2/show/NCT02454569?term=Vicente+Ferrer+HIV+Cohort+Study&amp;rank=1 (first received 15 May 2015). [NCT02454569] ">NCT02454569</a>). Therefore such data reflect a cohort of participants in a 'real‐world' setting. We presented these data separately as it would be misleading to pool findings from this cohort with the other cohorts. We reported the findings of all consecutive participants diagnosed with TBM between 23 December 2010 and 30 September 2014, which corresponded to 217 participants co‐infected with HIV and TBM. There were three children (aged 8, 9, and 13 years) and 214 adults older than 18 years, with a mean age of 38 years. Data on clinical severity were not reported. </p> <p>Local policy stated that participants without previous TB should receive six months of treatment while participants with previous TB should be treated for eight months. However, some clinicians treat patients with TBM for longer, independently of the condition of the patient according to the main investigator. Thereby, 20 participants were treated for six months (including one participant with previous TB) and 75 were treated for between seven to 16.7 months (including 19 participants with previous TB). The remaining 122 participants either died before the sixth month of ATT or received interrupted treatment, and the study authors therefore classified them as defaulters. Authors reported data on relapse, death, clinical cure and default, but did not reported data on poor adherence and adverse events. </p> </section> </section> <section id="CD012091-sec-0081"> <h4 class="title">Excluded studies</h4> <p>We have listed the reasons for excluding 122 studies in the '<a href="./references#CD012091-sec-0152" title="">Characteristics of excluded studies</a>' section. </p> </section> </section> <section id="CD012091-sec-0082"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD012091-fig-0003">Figure 3</a> for a summary of the 'Risk of bias' assessment of both group of cohorts receiving six months and more than six months of ATT. The 'Risk of bias' tables provide further details for supporting evidence in the '<a href="./references#CD012091-sec-0151" title="">Characteristics of included studies</a>' table. </p> <div class="figure" id="CD012091-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary for the cohorts treated for six months (left) and the cohorts treated for longer than six months." data-id="CD012091-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/image_n/nCD012091-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary for the cohorts treated for six months (left) and the cohorts treated for longer than six months. </p> </div> </div> </div> <section id="CD012091-sec-0083"> <h4 class="title">Cohorts treated for six months</h4> <section id="CD012091-sec-0084"> <h5 class="title">Detection bias</h5> <p>Three of the seven cohorts conducted routine follow‐up at greater than 18 months after completion of treatment, and we classified them as at low risk of detection bias for relapse and death after six months (<a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a>; <a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a>; <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>). Five cohorts presented a clear method of follow‐up during treatment and were at low risk of detection bias for death during treatment, clinical cure, default, and adherence (<a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a>; <a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a>; <a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a>; <a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a>; <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>). </p> </section> <section id="CD012091-sec-0085"> <h5 class="title">Attrition bias</h5> <p>Three cohorts followed up more than 95% of survivors, and we classified them as at low risk of attrition bias for relapse, and death after treatment (<a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a>; <a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a>; <a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a>). Five cohorts had less than 5% loss to follow‐up during treatment and were at low risk of attrition bias for death during treatment, clinical cure, default, and adherence (<a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a>; <a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a>; <a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a>; <a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a>; <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>). </p> </section> <section id="CD012091-sec-0086"> <h5 class="title">Performance bias</h5> <p>In four cohorts, more than 95% of the participants received the planned six months treatment, with few participants receiving prolonged treatment for specific reasons stated by the study authors (for example, modified and prolonged ATT due to severe adverse event), and we considered them as at low risk of performance bias (<a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a>; <a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a>; <a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a>; <a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a>). </p> </section> <section id="CD012091-sec-0087"> <h5 class="title">Confounding bias</h5> <p>In all the cohorts, we identified factors that may affect the main outcomes but that are not related to the duration of ATT, such as poor adherence and administration of corticosteroids. It is unclear how these factors would affect the findings and have classified them as unclear risk of confounding bias. </p> </section> </section> <section id="CD012091-sec-0088"> <h4 class="title">Cohorts treated for longer than six months</h4> <section id="CD012091-sec-0089"> <h5 class="title">Detection bias</h5> <p>Five of the 12 cohorts conducted routine follow‐up at greater than 18 months after completion of treatment and we classified them as at low risk of detection bias for relapse and death after six months of treatment (<a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a>; <a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a>; <a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a>; <a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a>; <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>). Seven cohorts presented a clear method of follow‐up during treatment and were at low risk of detection bias for death, clinical cure, default, and adherence (<a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a>; <a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a>; <a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a>; <a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a>; <a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a>; <a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a>; <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>). </p> </section> <section id="CD012091-sec-0090"> <h5 class="title">Attrition bias</h5> <p>Six cohorts followed‐up more than 95% of survivors and we judged them as at low risk of attrition bias for relapse and death after six months of treatment (<a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a>; <a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a>; <a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a>; <a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a>; <a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a>; <a href="./references#CD012091-bbs2-0018" title="VisudhiphanP , ChiemchanyaS . Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. The Journal of Pediatrics1989;114(5):875‐9. ">Visudhiphan 1989</a>). Four cohorts had less than 5% loss to follow‐up during treatment and we considered them as at low risk of attrition bias for death during treatment, clinical cure, default, and adherence (<a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a>; <a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a>; <a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a>; <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>). </p> </section> <section id="CD012091-sec-0091"> <h5 class="title">Performance bias</h5> <p>In three cohorts, it is very likely that all participants received the planned duration of treatment, with only one participant in one cohort receiving longer treatment due to severe adverse event, and we considered them as at low risk of performance bias (<a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a>; <a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a>; <a href="./references#CD012091-bbs2-0018" title="VisudhiphanP , ChiemchanyaS . Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. The Journal of Pediatrics1989;114(5):875‐9. ">Visudhiphan 1989</a>). </p> </section> <section id="CD012091-sec-0092"> <h5 class="title">Confounding bias</h5> <p>In all the cohorts, we identified factors that may have affected the main outcomes but that were not related to the duration of ATT, such as poor adherence and administration of corticosteroids. It is unclear how these factors would affect the findings and we have classified them as at unclear risk of confounding bias. </p> </section> </section> <section id="CD012091-sec-0093"> <h4 class="title">Additional cohort</h4> <p>We have presented our 'Risk of bias' assessment of the cohort reported by <a href="./references#CD012091-bbs2-0002" title="Alvarez‐UriaG , NaikPK , PakamR , BachuL , MiddeM . Natural history and factors associated with early and delayed mortality in HIV‐infected patients treated of tuberculosis under directly observed treatment short‐course strategy: a prospective cohort study in India. Interdisciplinary Perspectives on Infectious Diseases2012;2012:502012. [DOI: 10.1155/2012/502012] ">Alvarez‐Uria 2012</a> in the corresponding 'Risk of bias table' (see the '<a href="./references#CD012091-sec-0151" title="">Characteristics of included studies</a>' table). There was high risk of detection bias and unclear risk of attrition bias for outcomes that occurred during the follow‐up period, which ranged from one to 51 months. For outcomes that occurred during ATT, the risk of detection and attrition biases was low. We considered there was a high risk of performance bias as participants were treated from six to 16.7 months based on the decision of clinicians. </p> </section> </section> <section id="CD012091-sec-0094"> <h3 class="title" id="CD012091-sec-0094">Effects of interventions</h3> <p>See <a href="#CD012091-fig-0004">Figure 4</a> for the 'Summary of findings' table. We summarized the findings of the <a href="./references#CD012091-bbs2-0002" title="Alvarez‐UriaG , NaikPK , PakamR , BachuL , MiddeM . Natural history and factors associated with early and delayed mortality in HIV‐infected patients treated of tuberculosis under directly observed treatment short‐course strategy: a prospective cohort study in India. Interdisciplinary Perspectives on Infectious Diseases2012;2012:502012. [DOI: 10.1155/2012/502012] ">Alvarez‐Uria 2012</a> cohort separately in <a href="#CD012091-tbl-0007">Table 7</a>. </p> <div class="figure" id="CD012091-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="'Summary of findings' table." data-id="CD012091-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/image_n/nCD012091-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Summary of findings' table.</p> </div> </div> </div> <div class="table" id="CD012091-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Findings from the Alvarez‐Uria 2012 cohort</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Duration of ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> All</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> &lt; 6 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> 6 months<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> &gt; 6 months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b> Participant characteristics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Previous TB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Real duration of ATT received</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In those who received 6 months or more: 8.6 months</p> <p>(259 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 months</p> <p>(34.9 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> <p>(196 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2 months</p> <p>(276 days)</p> <p>Range from 212 to 501 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b> Outcomes at the end of ATT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 (43.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Default</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (13.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (23.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1<sup>b</sup> (5%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 (43.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 (76%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b> FU in survivors (from end of ATT)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lost to FU (0 days of FU after completing ATT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/123 (5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/29 (6.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/19 (5.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/75 (5.3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of FU among survivors, mean (range)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.9 months</p> <p>687 days (9 to 1539 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.4 months</p> <p>372 days (9 to 1272 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.5 months</p> <p>915 days (66 to 1539 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 months</p> <p>750 days (30 to 1511 days)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/89 (7.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/18 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/71<sup>d</sup> (9.9%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/116 (31.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/27 (66.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/18 (16.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/71 (22.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131/217 (60.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111/122 (91%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/20 (20%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/75 (21.3%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Note: we have presented the results based on complete‐case analysis.<br/> Abbreviations: ATT: antituberculous treatment; FU: follow‐up; HIV: human immunodeficiency virus; NA: not applicable; TB: tuberculosis; TBM: tuberculous meningitis.<br/> <sup>a</sup>We considered those participants treated between 180 and 209 days.<br/> <sup>b</sup>One participant had previous TB, thus the planned ATT was 8‐month regimen. The investigators classified this participant as a defaulter as he stopped ATT at 6 months.<br/> <sup>c</sup>Relapse is defined as the number of participants who have new symptoms and signs of TBM after resolution of disease and completion of ATT. None of the participants receiving less than 6‐month ATT completed their treatment. Therefore, we could not apply the term relapse to these participants. However, 5/27 participants who were defaulters and could be followed‐up, presented new symptoms and signs of TBM after stopping ATT, and were retreated.<br/> <sup>d</sup>We have presented the profile of these participants in <a href="#CD012091-tbl-0012">Table 12</a>. </p> </div> </div> <p>We have provided more details in <a href="#CD012091-tbl-0008">Table 8</a> and <a href="#CD012091-tbl-0009">Table 9</a> for cohorts treated for six months, and in <a href="#CD012091-tbl-0010">Table 10</a> and <a href="#CD012091-tbl-0011">Table 11</a> for cohorts treated for longer than six months. </p> <div class="table" id="CD012091-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Six months ATT: relapse, death, and clinical cure</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Prolonged ATT</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Losses to FU </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Length of FU after ATT, in months</b> </p> <p><b> Mean (range)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Relapse</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Death from any cause</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Death after 6 months ATT </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Clinical cure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> During ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> After ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(18 to 30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/28</p> <p>(32.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/28</p> <p>(3.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/28</p> <p>(71.4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(up to 24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/43</p> <p>(16.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/43</p> <p>(4.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/43</p> <p>(88.4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3</p> <p>(4 to 33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/29</p> <p>(13.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/29</p> <p>(86%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(16 to 45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/59</p> <p>(11.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/59</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52/59</p> <p>(88.1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/95</p> <p>(15.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/95</p> <p>(2.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82/95</p> <p>(86.3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/45</p> <p>(15.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/45</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/45</p> <p>(84.4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/159</p> <p>(5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/159</p> <p>(1.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153/159</p> <p>(96%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>458</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>28/332</b> </p> <p>(8.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0/415</b> </p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>39/381</b> </p> <p>(10.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Range</b> </p> <p><b>4 to 45</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3/369</b> </p> <p>(0.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 death</b> </p> <p><b>2 recoveries</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>58/458</b> </p> <p>(12.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8/458</b> </p> <p>(1.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>408/458</b> </p> <p>(89.1%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; FU: follow‐up; NA: not applicable; NDD: no disaggregated data; NR: not reported.<br/> Note: we have presented these results based on complete‐case analysis.<br/> <sup>a</sup>The study authors reported 4 participants lost to follow‐up and excluded them from their analyses. However, the study authors reported that these participants received 2, 2, 3, and 4 months of ATT respectively, and correspondence via letter after a mean period of 16.5 months indicated that all had fully recovery.<br/> <sup>b</sup>Attempted length of follow‐up. No data reported on the real follow‐up of the survivors.<br/> <sup>c</sup>Follow‐up was available for at least 6 months after completion of ATT in 27/38 survivors, and for less than 6 months in 7/38. </p> </div> </div> <div class="table" id="CD012091-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Six months ATT: default, poor adherence, treatment failure, and adverse effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Prolonged ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Losses to FU during ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Default</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Poor adherence</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Treatment failure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> All adverse effects (number of events)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Drug toxicity leading to ATT discontinuation or modification</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/29<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/29</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/95</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>458</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>28/332</b> </p> <p>(8.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0/415</b> </p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4/370</b> </p> <p>(1.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3/159</b> </p> <p>(1.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0/28</b> </p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>57</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13/197</b> </p> <p>(6.6%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; FU: follow‐up; NDD: no disaggregated data; NR: not reported.<br/> Note: we have presented these results based on complete‐case analysis.<br/> <sup>a</sup>The study authors reported that 4 participants were lost to follow‐up and excluded them from their analyses. However, the study authors reported that these participants received 2, 2, 3, and 4 months of ATT respectively, and correspondence via letter after a mean period of 16.5 months indicated that all had fully recovered. All four participants fit the definition of defaulter.<br/> <sup>b</sup>51 adverse effects were reported among the 184 participants recruited, without disaggregated data between those receiving 6 and 9 months of ATT.<br/> <sup>c</sup>ATT was discontinued in 17/184 participants, without disaggregated data between participants receiving 6 or 9 months of ATT. </p> </div> </div> <div class="table" id="CD012091-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">More than six months ATT: relapse, death, and clinical cure</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Duration of ATT (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Prolonged ATT </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Losses to FU </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Length of FU after ATT, in months</b> </p> <p><b> Mean (range)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Relapse</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Death from any cause</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Death after 6 months ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Clinical cure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> During ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> After ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/19<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/17<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/17</p> <p>(100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/25<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/22<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/22</p> <p>(100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 10</p> <p>(6 to 24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0/48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/37</p> <p>(13.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/37</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/30</p> <p>(83.3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 13</p> <p>(4 to 36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/35</p> <p>(5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/35</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/32</p> <p>(93.8%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 5.2</p> <p>(3.4 to 9.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/47</p> <p>(21.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/47</p> <p>(2.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/45</p> <p>(77.8%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/4</p> <p>(50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/4</p> <p>(50%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/4</p> <p>(50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/4</p> <p>(50%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 11.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individualised for all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/166 (15.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133/156</p> <p>(85.3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/28<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.8</p> <p>(12 to 29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/28</p> <p>(7.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/28</p> <p>(7.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/25</p> <p>(92%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(42 to 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64/180 (35.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/180</p> <p>(10.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119/166</p> <p>(71.7%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/215<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 death</p> <p>2 recoveries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69/215</p> <p>(32%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/215<sup>g</sup> </p> <p>(5.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137/186</p> <p>(73.7%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/42</p> <p>(16.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/42</p> <p>(83%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40/336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 53.4</p> <p>(IQR 47.4 to 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/296<sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 recoveries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>249/545 (45.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>336/535</p> <p>(62.8%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>HIV‐positive and isoniazid‐resistant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/25</p> <p>(24%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/25</p> <p>(20%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/25</p> <p>(96%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0018" title="VisudhiphanP , ChiemchanyaS . Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. The Journal of Pediatrics1989;114(5):875‐9. ">Visudhiphan 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(18 to 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/51</p> <p>(5.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/51</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/47</p> <p>(93.6%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 to 16</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1423</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32/472 and 166 individualized ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>87/1423</b> </p> <p>(6.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>56/985</b> </p> <p>(5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Range</b> </p> <p><b>6 to 84</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7/915</b> </p> <p>(0.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 death</b> </p> <p><b>6 recoveries</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>447/1423</b> </p> <p>(31.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>39/662</b> </p> <p>(5.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>984/1336</b> </p> <p>(73.7%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; FU: follow‐up; HIV: human immunodeficiency virus; IQR: interquartile range; NA: not applicable; NDD: no disaggregated data; NR: not reported.<br/> Note: we have presented these results based on complete‐case analysis.<br/> <sup>a</sup>There were 5 participants (2 in the 9‐month group, 3 in the 12‐month group) lost to follow‐up at the end of the 5 years follow‐up. No results were reported for these 5 participants, and it is unclear when they left the trial and what their outcomes were.<br/> <sup>b</sup>Attempted length of follow‐up. No data reported on the real follow‐up of the survivors.<br/> <sup>c</sup>Data could not be disaggregated by time until death. There were 7 deaths in the 6‐month group, 2 in the 9‐month group, and 2 in the 12‐month group; the study authors stated that over 90% of deaths occurred within the first 3 months of treatment in this study.<br/> <sup>d</sup>There were at least 3 deaths after six months of ATT. Indeed, three participants died in the second year from the start of ATT, due to nasopharyngeal carcinoma, acquired immune deficiency syndrome and chronic obstructive pulmonary disease. There were no disaggregated data among the deaths occuring within the first 12 months to report those occuring between the sixth and twelfth months from the start of ATT.<br/> <sup>e</sup>Three participants with poor compliance dropped out during the early stage of ATT and could not be followed‐up. One participant developed erythema multiform and had treatment suspended, then restarted with RHS. Another participant completed ATT but was lost to follow‐up afterwards.<br/> <sup>f</sup>Ten out of these 29 participants received modified ATT regimens with unknown reason, and the study authors excluded them from analysis.<br/> <sup>g</sup>Ten participants discharged against medical advice died.<br/> <sup>h</sup>143 participants received altered ATT regimen due to adverse events. It is unknown whether these participants received prolonged ATT.<br/> <sup>i</sup>These 3 participants were re‐treated for TB. It is unclear whether they were re‐treated because of TBM relapse or because of presenting another form of TB.<br/> <sup>j</sup>There were 50 deaths reported among the 296 survivors who completed the 9‐month treatment. We do not know if there were additional number of death between the sixth and ninth month of ATT, due to a lack of data reporting. The study authors could not determine how many of these deaths could be attributed to relapse. </p> </div> </div> <div class="table" id="CD012091-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">More than six months ATT: default, poor adherence, treatment failure, and adverse effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Duration of ATT (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Prolonged ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Losses to FU during ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Default</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Poor adherence</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Treatment failure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> All adverse effects (number of events)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Drug toxicity leading to ATT discontinuation or modification</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/19<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/30<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12/62</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/45<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 11.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individualised for all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/156</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/28<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/174</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/215<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/205</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89/535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143/535</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>HIV‐pos and H‐resistant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>i</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0018" title="VisudhiphanP , ChiemchanyaS . Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. The Journal of Pediatrics1989;114(5):875‐9. ">Visudhiphan 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 to 16</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1423</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32/472 and 166 individualized ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>87/1423</b> </p> <p>(6.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8/355</b> </p> <p>(2.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0/181</b> </p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95/681</b> </p> <p>(14.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>567</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>216/1299</b> </p> <p>(16.6%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; FU: follow‐up; H: isoniazid; HIV: human immunodeficiency virus; mo: months; NDD: no disaggregated data; NR: not reported.<br/> Note: we have presented these results based on complete‐case analysis.<br/> <sup>a</sup>There were 5 participants (2 in the 9‐month group, 3 in the 12‐month group) lost to follow‐up at the end of the 5 years follow‐up. No results were reported for these five participants, and it is unclear when they left the trial and what their outcomes were.<br/> <sup>b</sup>This study described 1 participant in the 8‐month ATT group as having treatment modified due to "inadequate clinical response", and 1 participant in the 12‐ to 16‐month ATT group as dying in the fifth month of treatment due to "therapeutic failure".<br/> <sup>c</sup>Four participants developed treatment failure, 3 during the fourth month of ATT, and 1 during the ninth month (who had concurrent pulmonary TB with proven isoniazid resistance). Three of these 4 participants died.<br/> <sup>d</sup>Three participants with poor compliance dropped out during the early stage of ATT and could not be followed‐up. One participant developed erythema multiform and had treatment suspended, then restarted with RHS. Another participant completed ATT but was lost to follow‐up afterwards.<br/> <sup>e</sup>Ten out of these 29 participants received modified ATT regimens with unknown reason, and the study authors excluded them from analysis.<br/> <sup>f</sup>The study authors stated that out of the 42 participants, 35 completed ATT, and 7 died. It is very likely that there was no defaulters, although this outcome was not clearly stated.<br/> <sup>g</sup>143 participants received altered ATT regimen due to adverse events. It is unknown whether these participants received prolonged ATT.<br/> <sup>h</sup>51 adverse effects are reported among the 184 participants, without disaggregated data between participants receiving 6 or 9 months of ATT.<br/> <sup>i</sup>ATT was discontinued in 17/184 participants, without disaggregated data between participants receiving 6 or 9 months of ATT. </p> </div> </div> <section id="CD012091-sec-0095"> <h4 class="title">Relapse</h4> <section id="CD012091-sec-0096"> <h5 class="title">Six months ATT</h5> <p>Up to the end of follow‐up, 3/369 participants (0.8%) from seven cohorts had relapsed. These three participants were from three different studies (<a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a>; <a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a>; <a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a>), had received different regimens, and relapsed between three weeks and three months after completing ATT. Their HIV status is unknown. They consisted of one adult (34 years of age), who died, and two children (one year and 11 years), who both recovered. In <a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a>, 5/7 children who had relapsed of TB infection from any organ in the whole cohort had missed doses, but authors did not report whether the case of TBM relapse was one of these five children. The child who relapsed in <a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> had ethionamide stopped and the dosages of isoniazid, rifampicin, and pyrazinamide halved due to poor appetite and nausea after three months of treatment. </p> </section> <section id="CD012091-sec-0097"> <h5 class="title">More than six months ATT</h5> <p>In 11 cohorts, 7/915 (0.8%) had relapsed during the follow‐up period. These participants arise from three different studies (<a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a>; <a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a>; <a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a>), and they all received nine‐month ATT with different regimens. They consisted of three children and four adolescents or adults. The HIV status was negative for one participant as <a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> excluded HIV‐positive people, and unknown for the remaining six participants: three in which the HIV status was not reported (<a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a>), and three in <a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a>, in which there were 98/545 HIV‐positive people, but the status of those who relapsed was not specified. They all recovered except one child who died. This child had culture‐positive CSF with fully sensitive <i>M. tuberculosis</i> on drug sensitivity testing at initial diagnosis and again at relapse, was retreated for nine months, and died 10 months after completing the second ATT regimen, despite having normal CSF analysis and negative CSF cultures. </p> </section> <section id="CD012091-sec-0098"> <h5 class="title">Additional cohort</h5> <p>None of the 18 participants treated for six months and followed up for 30.5 months on average presented relapse. From the 71 participants treated for longer than six months and followed‐up for a mean of 25 months, seven relapsed with fatal outcome in two cases. Time to relapse was between five days and 31 months. </p> <p>We have presented the profile of all participants who relapsed after completing ATT in <a href="#CD012091-tbl-0012">Table 12</a>. </p> <div class="table" id="CD012091-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Profile of participants who relapsed after completing ATT</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Gender, age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Duration of ATT received (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Time between end of ATT and relapse</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Six months ATT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Female, 34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease severity: stage III when first diagnosed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease severity: stage I at relapse</p> <p>It is unclear whether or not this participant missed doses in the continuation phase of treatment, but the study authors reported that missed doses were made up in all participants. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Female, 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease severity: stage I when first diagnosed, and stage II at relapse</p> <p>During the first course of ATT, Eth was stopped and the dosage of H and R halved to 10 mg/kg and Z halved to 20 mg/kg due to poor appetite and nausea after 3 months of treatment. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>More than six months ATT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, adult</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Child</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive CSF culture, fully sensitive on DST at initial diagnosis and relapse.</p> <p>Mild sequelae at the end of first course of ATT. Treated with ‘intensive therapy’ for 9 months, died 10 months after completing the second ATT regimen despite having normal CSF analysis and negative CSF cultures. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Child</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive CSF culture, fully sensitive on DST at initial diagnosis and relapse.</p> <p>Mild sequelae at the end of first course of ATT.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Child</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abnormal CSF and positive CSF culture, resistant to H and S on DST at initial diagnosis and relapse. </p> <p>Moderate sequelae at the end of first course of ATT.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>At five‐year follow‐up, these three participants self‐reported re‐treatment for TB. It is unclear whether this was for TBM or another form of TB. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Additional cohort</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD012091-bbs2-0002" title="Alvarez‐UriaG , NaikPK , PakamR , BachuL , MiddeM . Natural history and factors associated with early and delayed mortality in HIV‐infected patients treated of tuberculosis under directly observed treatment short‐course strategy: a prospective cohort study in India. Interdisciplinary Perspectives on Infectious Diseases2012;2012:502012. [DOI: 10.1155/2012/502012] ">Alvarez‐Uria 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, 32, HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This participant had previous TB</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, 65, HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, 31, HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This participant was cure after completing ATT for relapse. However, he died 12 months after completing the second ATT regimen. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, 32, HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This participant had previous TB</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, 32, HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This participant had previous TB</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, 45, HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, 13, HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; CSF: cerebrospinal fluid; DST: drug sensitivity tests; Eth: ethinamide; H: isoniazid; HIV: human immunodeficiency virus; R: rifampicin; TB: tuberculosis; Z: pyrazinamide. </p> </div> </div> </section> </section> <section id="CD012091-sec-0099"> <h4 class="title">Death from any cause</h4> <section id="CD012091-sec-0100"> <h5 class="title">Six months ATT</h5> <p>Overall, 58/458 participants (12.7%) who received or planned to receive six months ATT regimen across the seven cohorts, died from any cause. The proportion of death in each cohort ranges from 9/159 (5.7%) in <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> to 9/28 (32.1%) in <a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a>. <a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> is the cohort with higher proportion of participants with severe TBM at presentation (14/28; 50%), and the nine participants who died had severe disease. The <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> cohort receiving six months of ATT did not include any HIV‐positive participant and is the most recent study, conducted between 2006 and 2009, while the other cohorts were conducted between 1984 and 1994. </p> </section> <section id="CD012091-sec-0101"> <h5 class="title">More than six months ATT</h5> <p>Among participants who received or planned to receive more than six months ATT, 465/1423 participants (32.7%) died from any cause among the 12 cohorts, ranging from 0% (0/44) in <a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a> to 45.7% (249/545) and 50% (4/8) in <a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> and <a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> respectively. In <a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a>, the absence of death in uncertain as there were five participants without outcome reported. In <a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a>, 18% of the participants were HIV‐positive, which may explain the higher proportion of deaths in this cohort. </p> </section> <section id="CD012091-sec-0102"> <h5 class="title">Additional cohort</h5> <p>Overall, 131/217 (60.4%) participants died; 71.8% of them occurred during the first six months of ATT, and 13.7% in defaulters. </p> </section> </section> <section id="CD012091-sec-0103"> <h4 class="title">Death after six months of ATT</h4> <section id="CD012091-sec-0104"> <h5 class="title">Six months ATT</h5> <p>In participants that received six months regimens, death after six months of ATT coincides with death after completing treatment. All seven cohorts reported the timing of death and it was therefore possible to disaggregate the data to report the number of deaths that occurred after six months of treatment. Overall, 8/458 participants (1.7%) died after completing six months of ATT, which corresponded to 13.8% of the total number of deaths from any cause. Of these eight deaths, one was attributed to relapse, six to complications of TBM related to severe neurological sequelae, and there was no cause reported for the remaining death (see <a href="#CD012091-tbl-0013">Table 13</a>). </p> <div class="table" id="CD012091-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Causes of deaths after six months ATT</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Length of treatment (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Deaths after 6 months ATT</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b> Number of these deaths attributed to:</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Relapse</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Complications of TBM<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Non TB causes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Unknown</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b> Six months ATT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>More than six months ATT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>4 (HIV infection or post‐TBM complications)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.53 (mean)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; HIV: human immunodeficiency virus; mo: months; TB: tuberculosis; TBM: tuberculous meningitis. </p> <p><sup>a</sup>Death due to TBM complications can occur at any point in the course of treatment regardless of treatment duration, even after microbiological cure has been achieved. The complications leading to deaths reported in the included studies were all related to severe neurological sequelae.<br/> <sup>b</sup>There were 50 deaths reported among the 296 survivors who completed the nine‐month treatment. We do not know if there were additional number of death between the sixth and ninth month of ATT, due to a lack of data reporting. Authors could not determine how many of these deaths could be attributed to relapse.<br/> <sup>c</sup>Three participants died in the second year from the start of ATT, due to nasopharyngeal carcinoma, acquired immune deficiency syndrome, and chronic obstructive pulmonary disease. There were no disaggregated data among the deaths occuring within the first 12 months to report those occuring between the sixth and twelfth months from the start of ATT. </p> </div> </div> </section> <section id="CD012091-sec-0105"> <h5 class="title">More than six months ATT</h5> <p>Amont eight cohorts of participants receiving more than six months ATT, there were 39/662 participants (5.9%) who died after six months of ATT, corresponding to 8.7% of the total number of participants who died from any cause. One of these deaths was attributed to relapse, while 33 were due to complications of TBM related to severe neurological sequelae or non TB causes, and there were five deaths of unknown cause (see <a href="#CD012091-tbl-0013">Table 13</a>). The two cohorts with higher number of participants dying after six months of ATT were <a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a> (19/180 deaths) and <a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> (12/215), which are two cohorts with long follow‐up (42 to 84 months, and 51 months). In addition, the <a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> cohort reported 50/296 deaths after completing the nine‐month treatment, meaning that there were at least 50 participants who died after six months of ATT. The authors of the original paper could not determine how many of these deaths could be attributed to relapse. Finally, <a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a> reported three deaths during the second year from the start of ATT, attributable to causes no related to TBM. There is a lack of reporting to say how many of the 23 deaths reported during the first year occurred after the six months of ATT. </p> </section> <section id="CD012091-sec-0106"> <h5 class="title">Additional cohort</h5> <p>Among the survivors who completed at least six months of ATT, 19/89 (21.3%) participants died after six months of treatment: 3/18 (16.7%) were treated for six months and 16/71 (22.5%) were treated for longer than six months of ATT. Only two of these deaths were attributed to relapse in participants who were treated for 9.1 months and 10 months. </p> </section> </section> <section id="CD012091-sec-0107"> <h4 class="title">Clinical cure</h4> <section id="CD012091-sec-0108"> <h5 class="title">Six months ATT</h5> <p>In participants that received six months ATT, 408/458 (89.1%, seven cohorts) achieved clinical cure at the end of ATT. These findings were homogeneous across five cohorts. <a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> presented the lowest proportion of cases who achieved clinical cure (20/28; 71.4%), and <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> the highest proportion (153/159; 96%), which is consistent with the findings exposed in deaths of any cause outcome. </p> </section> <section id="CD012091-sec-0109"> <h5 class="title">More than six months ATT</h5> <p>In participants that received more than six months ATT, 989/1371 (72.1%, 12 studies) had achieved clinical cure at the end of ATT. There was high heterogeneity between the studies. The lowest proportions of participants with clinical cure are reported at 50% (4/8) in <a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> and at 62.8% (336/535) in <a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a>, which included 18% of HIV‐positive participants. The highest clinical cure rates were in <a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a> with 100% clinical cure (by complete‐case analysis, as authors did not report the final outcome for five participants), and <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> with 96% (24/25) in participants either HIV‐positive or with <i>M. tuberculosis</i> with monoresistance to isoniazid. </p> </section> <section id="CD012091-sec-0110"> <h5 class="title">Additional cohort</h5> <p>Overall, 94/217 (43.3%) participants achieved clinical cure at the end of ATT, which comprised of 19 participants treated for six months and 75 participants who were treated for longer. </p> </section> </section> <section id="CD012091-sec-0111"> <h4 class="title">Default</h4> <section id="CD012091-sec-0112"> <h5 class="title">Six months ATT</h5> <p>We were able to extract data on the number of participants who met our definition of default from five of the seven cohorts. There were 4/370 (1.1%) cases of default. The four cases came from the same cohort (<a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a>), in which the study authors reported that these participants received 2, 2, 3, and 4 months of ATT respectively, and correspondence via letter after a mean period of 16.5 months indicated that all had fully recovered. </p> </section> <section id="CD012091-sec-0113"> <h5 class="title">More than six months ATT</h5> <p>Six of the 12 cohorts reported data on default. There were 8/355 (2.3%) cases of default in this group: seven of them during the first six months of ATT, and the remaining one at an unclear time from the start of ATT. </p> </section> <section id="CD012091-sec-0114"> <h5 class="title">Additional cohort</h5> <p>Overall, there were 30/217 (13.8%) defaulters. It is not possible to classify these participants according to the duration of treatment that they were originally planned to receive, from the data available. </p> </section> </section> <section id="CD012091-sec-0115"> <h4 class="title">Poor adherence</h4> <p>One cohort that only received six months ATT reported poor adherence for 3/159 participants (1.9%; <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>), and two cohorts that received prolonged ATT reported on this outcome, with no cases reported cases with poor adherence (<a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a>; <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>). </p> </section> <section id="CD012091-sec-0116"> <h4 class="title">All adverse effects related to the ATT</h4> <p>We have described the adverse events as reported in the included studies (see <a href="#CD012091-tbl-0014">Table 14</a>). We are aware that some adverse events may be attributed to co‐intervention such as corticosteroids, or to complications of the TBM itself. </p> <div class="table" id="CD012091-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Number of adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Description of adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Related to ATT (events)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Leading to ATT discontinuation (participants)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Six months ATT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0021"> <li> <p>Elevation in ALT/AST/alkaline phosphatase/bilirubin: 15, leading to discontinuation of treatment with H/R and substitution with S for 3 to 7 days in 4 participants. </p> </li> <li> <p>Hyperuricaemia leading to 3‐day suspension of Z in 2 participants.</p> </li> <li> <p>Gastrointestinal symptoms 3 participants.</p> </li> <li> <p>Arthralgia 2 participants.</p> </li> <li> <p>Dizziness with nystagmus 1 participant.</p> </li> <li> <p>Rash 1 participant.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/639 TB cases had problems with the drug prescribed, but NDD for TBM.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0022"> <li> <p>1 severe hepatitis due to H. ATT was continued with R and E for 18 months with full recovery. </p> </li> <li> <p>No other adverse events reported.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0023"> <li> <p>Gastrointestinal bleeding or hyperglycemia was not observed as complications of prednisolone therapy. </p> </li> <li> <p>Adverse events were assessed and recorded; but results not reported.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0024"> <li> <p>Nausea and vomiting leading to stopping of Eth and reduction of RH doses. This case relapsed and was successfully re‐treated with HRZEth at full doses. </p> </li> <li> <p>Hepatotoxicity:</p> <ul id="CD012091-list-0025"> <li> <p>10 mild elevation of bilirubin leading to substitution of HRZEth with SE in 5 children, who were then re‐started on HRZEth when liver function normalised in 2 to 3 weeks; </p> </li> <li> <p>13 mild and transient elevation of ALT/AST, without treatment interruption.</p> </li> </ul> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Six and more than six months ATT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0026"> <li> <p>Anti‐TB drug‐induced hepatotoxicity (ADIH):</p> <ul id="CD012091-list-0027"> <li> <p>Grade 1 (mild) ALT 51 to 125 U/L: 18/184;</p> </li> <li> <p>Grade 2 (mild) ALT 126 to 250 U/L: 6/184; ATT changed to liver‐friendly regimens;</p> </li> <li> <p>Grade 3 (moderate) ALT 251 to 500 U/L: 6/184; ATT changed to liver‐friendly regimens;</p> </li> <li> <p>Grade 4 (severe) ALT &gt; 500 U/L: 2/184; ATT changed to liver‐friendly regimens.</p> </li> </ul> </li> </ul> </p> <p>In all ADIH cases from grade 2 severity, change to liver‐friendly regimens resulted in normalization of liver enzymes (medium duration 7 days, range 3 to 16 days) and the original regimen was restarted (stepwise) without recurrence. </p> <p> <ul id="CD012091-list-0028"> <li> <p>Significant nausea and vomiting: 19/184</p> </li> </ul> </p> <p>Eth was substituted with E in 3 cases, solving the problem. In the remaining 16 cases, administration of Eth at night solved the problem. </p> <p>Of these 19 participants, 8 had drug‐induced hepatotoxicity and 11 had normal liver function. In these 11 either substituting Eth for E or giving Eth at night resolved the nausea and vomiting. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>More than six months ATT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12/72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD012091-list-0029"> <li> <p>2 nausea and vomiting.</p> </li> <li> <p>10 toxic hepatitis with a moderate increase in hepatic enzyme levels. HR were discontinued in these cases for a short time (3 to 5 days) and after recovery, reinstituted. </p> </li> <li> <p>2 hearing loss. S was stopped.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0030"> <li> <p>8 paradoxical reactions (increased size of tuberculoma or development of new tuberculoma, 2 died) </p> </li> <li> <p>4 hepatitis: 1 at the end of 1<sup>st</sup> month; 2 at 4 months; 1 at 7 months. One case of hepatitis led to discontinuation of ATT at 124 days. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin rash, hearing difficulty, impaired liver function with elevated ALT, and blurring of vision. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0031"> <li> <p>6 participants with 2 to 3‐fold elevation of ALT/AST ± alkaline phosphatase level (no discontinuation of ATT) during the early weeks of treatment. </p> </li> <li> <p>14 participants with asymptomatic hyperuricemia (90 to 140 mg/L) during the first 2 months of ATT when Z was given, 8 received probenecid. </p> </li> <li> <p>1 erythema multiforme from Z. All drugs were discontinued. After rashes healed, ATT was continued with HRS with full recovery. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (36*)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (36*)/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0032"> <li> <p>4 cases according to the 1989 publication (*3 cases according to the 1986 publication) with ocular complications: ethambutol was discontinued and PAS substituted, even though it was clear that the problem was unrelated to drugs. </p> </li> <li> <p>30 jaundice: R (first study) or both RZ (second and third studies) were discontinued while the other drugs were continued. </p> </li> <li> <p>2 skin reactions: R was stopped in 1 participant and the participant recovered completely; all anti‐tuberculosis drugs were withheld for 1 week in the other participant and the participant recovered fully. The treatment was resumed uneventfully. </p> </li> <li> <p>1 arthralgia: Z was stopped and the swelling diminished during the next 3 weeks. He could not be followed up further as he died of TBM. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 participants developed jaundice with abnormal liver function tests</p> <p>5 participants had an increase in hepatic enzymes levels without clinical jaundice</p> <p>For these 15 participants: R and Z were terminated and other drugs were continued.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0033"> <li> <p>1 drug‐induced hepatitis causing death.</p> </li> <li> <p>2 participants with clinical jaundice and persistent vomiting who were converted to daily regimen. </p> </li> <li> <p>No other adverse events reported.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155/545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>329 non‐severe; 71 severe</p> <p> <ul id="CD012091-list-0034"> <li> <p>Subclinical hepatitis: 92 non‐severe; 0 severe.</p> </li> <li> <p>Clinical hepatitis: 9 non‐severe; 8 severe.</p> </li> <li> <p>Gastrointestinal bleeding: 10 non‐severe; 5 severe.</p> </li> <li> <p>Bacterial sepsis: 12 non‐severe; 7 severe.</p> </li> <li> <p>Septic shock: 0 non‐severe; 3 severe.</p> </li> <li> <p>Brain herniation syndrome: 0 non‐severe; 5 severe.</p> </li> <li> <p>Decrease in visual acuity: 16 non‐severe; 14 severe.</p> </li> <li> <p>Hyponatremia: 11 non‐severe; 7 severe.</p> </li> <li> <p>Hyperglycaemia: 5 non‐severe; 0 severe.</p> </li> <li> <p>Hypertension: 5 non‐severe; 0 severe.</p> </li> <li> <p>Vertigo: 39 non‐severe; 0 severe.</p> </li> <li> <p>Deafness: 8 non‐severe; 6 severe.</p> </li> <li> <p>Cushing’s features: 12 non‐severe; 0 severe.</p> </li> <li> <p>Pruritus: 12 non‐severe; 0 severe.</p> </li> <li> <p>Polyarthralgia: 5 non‐severe; 0 severe.</p> </li> <li> <p>Streptomycin reaction: 4 non‐severe; 0 severe.</p> </li> <li> <p>Rifampin flu: 7 non‐severe; 0 severe.</p> </li> <li> <p>Rash: 13 non‐severe; 1 severe.</p> </li> <li> <p>Other (other events that were reported fewer than 4 times): 76 non‐severe; 15 severe.</p> </li> </ul> </p> <p>ATT was stopped or modified in 143 participants.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0018" title="VisudhiphanP , ChiemchanyaS . Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. The Journal of Pediatrics1989;114(5):875‐9. ">Visudhiphan 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0035"> <li> <p>4 participants: elevation of serum AST/ALT levels à rifampicin dose decreased to 10 mg/kg/day in 3 participants, and to 8 mg/kg/day in the 4th participant. </p> </li> <li> <p>8 participants with mild gastrointestinal disturbances.</p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ALT: alanine transaminase; AST: aspartate transaminase; ATT: antituberculous treatment, E: ethambutol; Eth: ethionamide; H: isoniazid; HIV: human immunodeficiency virus; NDD: no disaggregated data; NR: not reported; R: rifampicin; Z: pyrazinamide </p> </div> </div> <section id="CD012091-sec-0117"> <h5 class="title">Six months ATT</h5> <p>Three cohorts reported disaggregated data on adverse effects related to ATT. There was inconsistency in the way the three cohorts reported the adverse events. <a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a> only reported one case of severe adverse event (severe hepatitis) among 29 participants, while <a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> and <a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> reported 24 and 32 adverse events respectively among 28 and 95 participants, which comprised a more comprehensive list of adverse events, ranging from mild and transient elevation of transaminases to severe elevation of transaminases and uric acid. <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> reported adverse events for all participants that received six and more than six months of treatment. <a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a> reported all adverse effects for the whole cohort of participants with TB from any organ, without disaggregated data for those with TBM. </p> </section> <section id="CD012091-sec-0118"> <h5 class="title">More than six months ATT</h5> <p>Nine cohorts reported a comprehensive list of adverse effects related to treatment, although there was inconsistency in the methods the study authors used to detect adverse events. In some studies investigators actively looked for adverse events, while in other studies investigators only reported on participants who reported symptoms. </p> </section> </section> <section id="CD012091-sec-0119"> <h4 class="title">Drug toxicity leading to the discontinuation or modification of the treatment regimen</h4> <section id="CD012091-sec-0120"> <h5 class="title">Six months ATT</h5> <p>There were 13/197 (6.6%) participants from four cohorts who had their ATT interrupted due to hepatotoxicity or significant nausea and vomiting (<a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a>; <a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a>; <a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a>; <a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a>). In <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>, drug toxicity led to discontinuation of ATT in 17/184, without disaggregated data between participants receiving six and more than six months of ATT. </p> </section> <section id="CD012091-sec-0121"> <h5 class="title">More than six months ATT</h5> <p>There were 216/1299 (16.6%) participants from 10 cohorts who had their ATT discontinued or modified due to a range of adverse events (see <a href="#CD012091-tbl-0014">Table 14</a>). There was inconsistency across the cohorts on how these participants were managed. </p> </section> </section> <section id="CD012091-sec-0122"> <h4 class="title">Additional TB outcomes reported by studies</h4> <section id="CD012091-sec-0123"> <h5 class="title">Six months ATT</h5> <p>None of the cohorts reported treatment failure.</p> <p>Four cohorts reported 123/358 participants with neurodisability after treatment completion. There is high inconsistency across studies regarding the neurological sequelae reported and in the way of diagnosing them. </p> </section> <section id="CD012091-sec-0124"> <h5 class="title">More than six months ATT</h5> <p>Three cohorts reported data on treatment failure. In <a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a>, one participant is reported to died due to treatment failure after five months of therapy, and ATT was modified in another participant due to "inadequate clinical response". In <a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a>, four participants developed treatment failure (three during the fourth month of therapy, and one with isoniazid resistance open case of pulmonary TB during the nine month of therapy). <a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> reported 89 participants with "onset of new focal neurologic signs or a fall in the Glasgow coma score of two points or more for two or more days after more than seven days of clinical stability or improvement at any time after randomization", after a median of 41 days in the dexamethasone group and 38 days in the placebo group from starting treatment. Although the study authors defined these cases as relapse, they did not meet our definition of relapse as they deteriorated during ATT; we classified them as treatment failure. Lack of an agreed definition of treatment failure in TBM, and differences in monitoring of participants during therapy, are likely to have led to the marked discrepancy in reporting of this outcome between studies. </p> <p>Nine cohorts reported 352/1304 participants with neurodisability at the end of treatment. There is high inconsistency across studies in the neurological sequelae reported and in the way of diagnosing them. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012091-sec-0125" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012091-sec-0125"></div> <section id="CD012091-sec-0126"> <h3 class="title" id="CD012091-sec-0126">Summary of main results</h3> <p>The seven cohorts treated for six months included 458 participants from Thailand, South Africa, Ecuador, and Papua New Guinea, and only one study was conducted after the year 2000. The 12 cohorts treated for longer (eight to 16 months) included 1423 participants from India, Thailand, South Africa, China, Romania, Turkey, and Vietnam, with four conducted between 2001 and 2011. The proportion of participants classified as having stage III disease (severe) was higher in the cohorts treated for six months, but the proportion with known concurrent HIV was higher in the cohorts that were treated for longer. The diagnosis was confirmed on culture in 56/254 (22%) participants treated for six months versus 470/1264 (37%) treated for longer (in studies where this was clearly stated). Although there were variations in the treatment regimens, most cohorts received isoniazid, rifampicin, and pyrazinamide during the intensive phase. </p> <p>Three out of the seven cohorts treated for six months and five of the 12 cohorts treated for longer achieved follow‐up beyond 18 months after completing treatment. All studies had potential sources of bias in their estimation of the relapse rate, and comparisons between the cohorts could be confounded. </p> <p>Relapse was an uncommon event in both groups of cohorts of participants treated for six months and longer than six months, and only one death was attributed to relapse in each group. </p> <p>Overall, the proportion of participants who died was higher in the cohorts treated for longer than six months, but most deaths occurred during the first six months regardless of treatment duration. This difference is not due to the treatment duration, but rather indicates that there is likely to be substantial clinical heterogeneity between the six months cohorts and the longer treatment cohorts. The disease severity is unlikely to be the main cause of this difference in the mortality rate in these cohorts, as the proportion of participants with severe tuberculous meningitis (TBM) (grade III) was higher in the cohorts treated for six months. The reason for the higher mortality rate in the group of cohorts treated for longer than six months is likely multifactorial. Delay in starting antituberculous treatment (ATT), drug resistance, drug‐induced hepatitis, adherence to ATT, quality of supportive care, HIV status, and drug regimens could all contribute to this difference between the groups of cohorts. </p> <p>As there was a higher proportion of deaths during ATT in the longer treatment cohorts, the proportion of participants that achieved clinical cure was higher in the group of cohorts treated for six months. </p> <p>Few participants defaulted from treatment in both groups of cohorts, and adherence was poorly reported. </p> <p>Most of the study authors reported on adverse events, but the level of detail in reporting varied significantly, and we were unable to draw any clear conclusions about rates of adverse events between the two groups of cohorts. </p> <p>The main difference between the <a href="./references#CD012091-bbs2-0002" title="Alvarez‐UriaG , NaikPK , PakamR , BachuL , MiddeM . Natural history and factors associated with early and delayed mortality in HIV‐infected patients treated of tuberculosis under directly observed treatment short‐course strategy: a prospective cohort study in India. Interdisciplinary Perspectives on Infectious Diseases2012;2012:502012. [DOI: 10.1155/2012/502012] ">Alvarez‐Uria 2012</a> cohort and the rest of the included cohorts was that all participants in the <a href="./references#CD012091-bbs2-0002" title="Alvarez‐UriaG , NaikPK , PakamR , BachuL , MiddeM . Natural history and factors associated with early and delayed mortality in HIV‐infected patients treated of tuberculosis under directly observed treatment short‐course strategy: a prospective cohort study in India. Interdisciplinary Perspectives on Infectious Diseases2012;2012:502012. [DOI: 10.1155/2012/502012] ">Alvarez‐Uria 2012</a> trial were HIV‐positive, and that they were managed in a "real‐world" setting, contrary to the other cohorts in which participants were under trial or study conditions. The relapse rate was higher, with no cases among the 18 survivors who completed six months of ATT, and seven cases among the 71 survivors treated for longer than six months. In this cohort, it would be misleading to compare participants treated for six and more than six months, as we do not know whether the baseline characteristics of the participants were comparable. The mortality rate was high (131/217, 60.4%), and 71.8% of the deaths occurred during the first six months of treatment, similarly to the rest of the cohorts included in the review. The proportion of defaulters was higher than in the rest of the included studies (13.8%). This could represent a more accurate picture of the real proportion of defaulters among HIV‐positive people in an operational setting who must take a high number of prescribed drugs. </p> </section> <section id="CD012091-sec-0127"> <h3 class="title" id="CD012091-sec-0127">Overall completeness and applicability of evidence</h3> <p>This Cochrane review includes adults and children from a variety of geographical settings, including countries in South‐East Asia and Africa with a high tuberculosis (TB) burden (<a href="./references#CD012091-bbs2-0190" title="World Health Organization. Global Tuberculosis Report 2015. http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1 (accessed 22 March 2016). ">WHO 2015</a>). </p> <p>Only one cohort in the group of studies treating for six months reported the HIV status of the participants, and in this study HIV‐positive people were all treated for nine months (<a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>). Five cohorts where participants received more than six months mentioned HIV status: two cohorts explicitly excluded HIV‐positive people (<a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a>; <a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a>), and three cohorts included 122/376 HIV‐positive people (<a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a>; <a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a>; <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a>). In addition, the cohort from <a href="./references#CD012091-bbs2-0002" title="Alvarez‐UriaG , NaikPK , PakamR , BachuL , MiddeM . Natural history and factors associated with early and delayed mortality in HIV‐infected patients treated of tuberculosis under directly observed treatment short‐course strategy: a prospective cohort study in India. Interdisciplinary Perspectives on Infectious Diseases2012;2012:502012. [DOI: 10.1155/2012/502012] ">Alvarez‐Uria 2012</a> reported 217 participants co‐infected with HIV. Further evidence relating to the duration of ATT in HIV‐positive people with TBM is needed. </p> <p>Six of the seven cohorts treated for six months and 11 of the 12 cohorts treated for longer than six months presented the three stages of clinical severity, with around half of participants in stage II in all cohorts. Results from this review are therefore applicable for all stages of clinical severity of the disease at presentation. </p> <p>In this review, we have restricted the inclusion of studies to those that included ATT regimens that contained rifampicin. All six months course regimens contained at least isoniazid, rifampicin, and pyrazinamide during the intensive phase, and 1250/1423 participants treated for longer also received these three drugs, which reflect the current first‐line regimens. The range of single daily doses used is mostly concordant with current recommendations. </p> <p>We also restricted study inclusion to studies that reported participants with drug‐sensitive TBM. <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> excluded children with multidrug‐resistant TBM. However, this study included those with isoniazid‐monoresistance. For these participants, the planned treatment consisted in a fluoroquinolone and terizidone in addition to the standard ATT for nine months. We decided to include this study as data on isoniazid‐monoresistant cases (three children) were disaggregated. Across all studies, most cases did not have a <i>M. tuberculosis</i>‐positive culture. Thus, the drug‐sensitivity pattern was unavailable and we cannot be sure that some cases were not caused by drug‐resistant strains. However, if any, this would have affected few cases, as prevalence of drug‐resistant strains was lower in the period when most of the studies were conducted. Hence, results from this review are not applicable to drug‐resistant TBM. </p> <p>Adjunctive treatment with corticosteroids is currently recommended in all cases of TBM to reduce death (<a href="./references#CD012091-bbs2-0172" title="PrasadK , SinghMB , RyanH . Corticosteroids for managing tuberculous meningitis. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD002244.pub4] ">Prasad 2016</a>). Most of the recruited participants received corticosteroids, which means that applicability of the results is unlikely to be affected by this co‐intervention. </p> </section> <section id="CD012091-sec-0128"> <h3 class="title" id="CD012091-sec-0128">Quality of the evidence</h3> <p>We derived the results from single‐arm studies and not direct randomized comparisons, although some were arms within randomized controlled trials (RCTs) performed for other purposes. As such, participant characteristics, comorbidities, the severity of the disease, differences in ATT regimens, drug resistance, drug‐related adverse events, quality of supportive care, and method of follow‐up could be different between the two groups, and making causal inferences on the basis of potentially confounded cohorts is problematic. Because of this substantial clinical and methodological heterogeneity between the studies, we did not attempt to perform a meta‐analysis or perform a Grading of Recommendations, Assessment, Development and Evaluation (GRADE) assessment. Nevertheless, relapse rates were low after treatment completion in both groups. </p> </section> <section id="CD012091-sec-0129"> <h3 class="title" id="CD012091-sec-0129">Potential biases in the review process</h3> <p>We attempted to limit bias by following the rigorous methods provided by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012091-bbs2-0164" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). The Cochrane Infectious Diseases Group Information Specialist performed the literature search without language restrictions, and as such it is unlikely that we missed any large studies. We attempted to identify unpublished studies by contacting relevant researchers in this area, but only one study author replied. Thus, we cannot rule out the possibility that we missed some unpublished data. Also, we were unable to assess publication bias because no study directly compares six versus longer than six months of ATT. We attempted to limit bias in the selection process, data extraction, and assessment of the quality of the included studies by conducting these processes independently and by comparing results between at least two review authors. </p> </section> <section id="CD012091-sec-0130"> <h3 class="title" id="CD012091-sec-0130">Agreements and disagreements with other studies or reviews</h3> <p>The findings of this Cochrane Review are similar to those of a systematic review conducted by <a href="./references#CD012091-bbs2-0185" title="vanLoenhout‐RooyackersJH , KeyserA , LaheijRJF , VerbeekALM , van derMeerJWM . Tuberculosis meningitis: is a 6‐month treatment regimen sufficient?. International Journal of Tuberculosis and Lung Disease2001;5(11):1028‐35. ">van Loenhout‐Rooyackers 2001</a>, who concluded, based on the results of 11 included studies, that six months regimens with at least isoniazid, rifampicin, and pyrazinamide were sufficient for participants with fully drug sensitive TBM. This review was similar to our review in that the included studies were all non‐randomized observational studies. Completion of treatment was 81% in participants that received six months regimens and 85% in those that received longer regimens. There were 2/131 and 0/591 participants with relapse in the six months regimen group and longer ATT group respectively. Another systematic review, which belongs to a series that addressed the scientific evidence behind the World Health Organization (WHO)’s recommendations, reviewed the most appropriate ATT for TBM and drew similar conclusions regarding length of treatment, based on four prospective and retrospective observational cohorts (<a href="./references#CD012091-bbs2-0191" title="WoodfieldJ , ArgentA . Evidence behind the WHO guidelines: hospital care for children: what is the most appropriate anti‐microbial treatment for tuberculous meningitis?. Journal of Tropical Pediatrics2008;54(4):220‐4. [DOI: 10.1093/tropej/fmn063] ">Woodfield 2008</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012091-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/urn:x-wiley:14651858:media:CD012091:CD012091-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/image_t/tCD012091-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Possible disadvantages of prolonged and short‐course antituberculous regimens for treating people with TBM." data-id="CD012091-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/image_n/nCD012091-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Possible disadvantages of prolonged and short‐course antituberculous regimens for treating people with TBM. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/image_n/nCD012091-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012091-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/urn:x-wiley:14651858:media:CD012091:CD012091-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/image_t/tCD012091-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012091-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/image_n/nCD012091-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/image_n/nCD012091-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012091-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/urn:x-wiley:14651858:media:CD012091:CD012091-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/image_t/tCD012091-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary for the cohorts treated for six months (left) and the cohorts treated for longer than six months." data-id="CD012091-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/image_n/nCD012091-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary for the cohorts treated for six months (left) and the cohorts treated for longer than six months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/image_n/nCD012091-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012091-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/urn:x-wiley:14651858:media:CD012091:CD012091-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/image_t/tCD012091-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="'Summary of findings' table." data-id="CD012091-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/image_n/nCD012091-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>'Summary of findings' table.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/media/CDSR/CD012091/image_n/nCD012091-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD012091-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of cohort studies that administered six months ATT</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Setting</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b> Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> ATT regimens</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Duration of FU after ATT, in months</b> </p> <p><b> Mean (range)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Centre</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Adults/children</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> HIV status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> MRC stages of the disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ecuador</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 4/28</p> <p>II: 10/28</p> <p>III: 14/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HRZ/4HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(18 to 30)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Papua New Guinea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HRZS/4(HR)<sub>2</sub> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(up to 24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 7/29</p> <p>II: 12/29</p> <p>III: 10/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HRZS/4HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3</p> <p>(4 to 33)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 9/59</p> <p>II: 40/59</p> <p>III: 10/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HRZS/4HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(16 to 45)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 4/95</p> <p>II: 52/95</p> <p>III: 39/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6HRZEth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 8/45</p> <p>II: 25/45</p> <p>III: 12/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HRZS/4HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 6 months: 27/38</p> <p>Less than 6 months: 7/38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐negative or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 22/184<sup>c</sup> </p> <p>II: 98/184</p> <p>III: 84/184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6HRZEth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 24</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment, E: ethambutol; Eth: ethionamide; FU: follow‐up; H: isoniazid; HIV: human immunodeficiency virus; MRC: Medical Research Council; NR: not reported; R: rifampicin; Z: pyrazinamide.<br/> <sup>a</sup>In this prospective cohort study, data are reported for three successive cohorts in the same centre over time. The first cohort received a 12‐month regimen with 2/4 participants receiving rifampicin, the second a 9‐month regimen with all participants receiving rifampicin, and the third received a 6‐month regimen with all participants receiving rifampicin and pyrazinamide.<br/><br/> <sup>b</sup>HIV‐positive children were treated with a 9‐month regimen due to a perceived slower response to treatment.<br/><br/> <sup>c</sup>There were no diaggregated data for clinical severity of the disease between the cohort of HIV‐negative participants receiving 6 months of treatment and the cohort of HIV‐positive participants receiving 9‐month ATT. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of cohort studies that administered six months ATT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012091-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Diagnosis of TBM: clinical and radiological characteristics in cohorts that received six months ATT</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Previous history of TB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Known contact with TB patient</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PPD skin test positive</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuroimaging</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abnormal chest X‐ray</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Done in all participants.</p> <p>Abnormal findings in 19/28.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/38 (≥ 15 mm or ≥ 10 mm with BCG scar)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Myelogram in participants with partial spinal block.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CT scan in 18 participants.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/29</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CT scan: abnormal findings in 31/37. Myelogram for participants with paraparesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/95 between 10 mm and 15 mm,</p> <p>84/95 ≥ 15 mm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CT scan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41/95</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CT scan on admission: bilateral basal ganglia infarction in all 7 cases who died before completing ATT. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Done, NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; BCG: Bacillus Calmette–Guérin; CT: computed tomography; NR: not reported; PPD: purified protein derivative.<br/> <sup>a</sup><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> and <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> also reported cohorts of participants treated for longer than 6 months, but no disaggregated data are provided on clinical features between both cohorts. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Diagnosis of TBM: clinical and radiological characteristics in cohorts that received six months ATT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012091-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Diagnosis of TBM: microbiological and other diagnostic characteristics in cohorts that received six months ATT</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>CSF</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Other diagnostic methods for TB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Diagnostic classification</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cell count, protein and glucose content</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Positive AFB smear</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Positive culture</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other tests performed in CSF</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bacteriologically confirmed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinically diagnosed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ELISA for BCG antibodies,</p> <p>ADA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteriological analyses of sputum, gastric aspirate, and urine.</p> <p>1 lymph node biopsy, 1 culture from abscess drainage. Autopsy findings.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Done but NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sputum specimens, fasting gastric aspirates, and pleural fluid for microscopy and culture. </p> <p>Lymph node biopsy for histology and culture.</p> <p>Abdominal ultrasound.</p> <p>BCG vaccine scar.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/29</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pyogenic bacterial and fungal culture, latex agglutination test for bacterial and cryptococcal Ag and cytologic study for malignancy; results NR </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 or 6/59<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 or 54/59<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DST</p> <p>Air encephalogram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastric aspirate for microscopy and culture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77/95</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence of a BCG vaccine scar in 28/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCR for MTB in CSF 2 specimens<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Culture of gastric washings: 43/155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168/184</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Abbreviations: ADA: adenosine deaminase activity; AFB: acid‐fast bacillus; Ag: antigen; BCG: Bacillus Calmette–Guérin; CSF: cerebrospinal fluid; DST: drug sensitivity tests; ELISA: enzyme‐linked immunosorbent assay; NR: not reported; MTB: <i>Mycobacterium tuberculosis</i>; PCR: polymerase chain reaction; PPD: purified protein derivative.<br/> <sup>a</sup>Unclear whether the specimens with positive stain were also culture positive.<br/> <sup>b</sup><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> and <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> also reported cohorts of participants treated for longer than 6 months, but no disaggregated data are provided on CSF characteristics and diagnosis classification between the cohorts.<br/> <sup>c</sup>The study authors stated that PCR was not done routinely, but did not report how many specimens were tested this way. The 2 positive PCR specimens were also culture positive. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Diagnosis of TBM: microbiological and other diagnostic characteristics in cohorts that received six months ATT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012091-tbl-0004"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Description of cohort studies that administered more than six months ATT</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Setting</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b> Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> ATT regimens</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Duration of ATT (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Duration of FU after ATT, in months <br/> Mean (range)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Centre</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Adults/c <br/> hildren</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> HIV status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Severity of the disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Romania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3HRZ/6HR<sub>2</sub> <br/> (19 cases)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3HR/3HR<sub>2</sub>/6H<sub>2</sub> <br/> (25 cases)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Multicentre; university hospitals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I: 7/72</p> <p>II: 34/72</p> <p>III: 31/72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HRZS/6HR <br/> (37 cases) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 10</p> <p>(6 to 24)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HRZE <br/> (19 cases) </p> <p>HRES <br/> (6 cases) </p> <p>HRZS <br/> (6 cases) </p> <p>HRZES <br/> (3 cases) </p> <p>HRE <br/> (1 case) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 13</p> <p>(4 to 36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HIV positive excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I: 15/43</p> <p>II: 24/43</p> <p>III: 4/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2(HRZS)<sub>3</sub>/7(HR)<sub>3</sub> <br/> (41 cases) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Median 5.2</p> <p>(IQ 3.4 to 9.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2(HREZS)<sub>3</sub>/1(HREZ)<sub>3</sub> /7(HR)<sub>3</sub> (2 cases) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>I: 0/8</p> <p>II: 4/8</p> <p>III: 4/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HRS/7HR <br/> (4 cases) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HSE/10HE <br/> (2 cases) </p> <p>2RSE/10RE <br/> (2 cases) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> <p>(Hong Kong)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre; tertiary and secondary hospitals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults and children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 HIV positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 91/166</p> <p>II: 69/166</p> <p>III: 6/166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HRZES</p> <p>(66 cases)</p> <p>HRZE <br/> (63 cases) </p> <p>HRZS <br/> (24 cases) </p> <p>HRZ <br/> (8 cases) </p> <p>HRE <br/> (2 cases) </p> <p>SHRE <br/> (1 case) </p> <p>HZE <br/> (1 case) </p> <p>HR <br/> (1 case) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.53</p> <p>(mean)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 4/28</p> <p>II: 18/28</p> <p>III: 6/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2HRZS/7HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.8</p> <p>(12 to 29)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre; tertiary hospitals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 24/180</p> <p>II: 139/180</p> <p>III: 17/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2SHR/4S<sub>2</sub>EH/6EH <br/> (77 cases) </p> <p>2SHRZ/10EH <br/> (29 cases) </p> <p>2R<sub>2</sub> SHZ/10EH <br/> (74 cases) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(42 to 84)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre; tertiary hospitals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 45/215</p> <p>II: 160/215</p> <p>III: 10/215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2SHE(RZ)<sub>3</sub>/7(RH)<sub>2</sub> <br/> (89 cases) </p> <p>2SHE(RZ)<sub>2</sub>/7(RH)<sub>2</sub> <br/> (96 cases) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV positive excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: NDD</p> <p>II: NDD</p> <p>III: 21/42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2(HREZ)<sub>3</sub>/7(HR)<sub>3</sub> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vietnam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicentre; tertiary hospitals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults and adolescents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>436 HIV negative</p> <p>98 HIV positive</p> <p>11 unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 176/545</p> <p>II: 247/545</p> <p>III: 122/545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3RHZS/6RHZ <br/> (399 HIV negative) </p> <p>3RHZE/6RHZ <br/> (98 HIV positive) </p> <p>3RHZES/6RHZ <br/> (43 previously treated) </p> <p>HZE <br/> (2 cases) </p> <p>SE <br/> (1 case) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 53.4</p> <p>(IQ 47.4 to 57)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 HIV positive;</p> <p>3 unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 22/184 <sup>c</sup> </p> <p>II: 98/184</p> <p>III: 84/184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9HRZEth<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0018" title="VisudhiphanP , ChiemchanyaS . Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. The Journal of Pediatrics1989;114(5):875‐9. ">Visudhiphan 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thailand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tertiary centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: 5/51</p> <p>II: 25/51</p> <p>III: 21/51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12HR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(18 to 84)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment, E: ethambutol; Eth: ethionamide; FU: follow‐up; H: isoniazid; HIV: human immunodeficiency virus; IQ: interquartile range; MRC: Medical Research Council; NR: not reported; R: rifampicin; Z: pyrazinamide<br/> <sup>a</sup>It is unclear whether streptomycin twice weekly was also administered in both regimens in the first 3 months.<br/> <sup>b</sup>In this prospective cohort study, data are reported for 3 successive cohorts in the same centre over time. The first cohort received a 12‐month regimen with 2/4 participants receiving rifampicin, the second a 9‐month regimen with all participants receiving rifampicin, and the third received a 6‐month regimen with all participants receiving rifampicin and pyrazinamide.<br/><br/> <sup>c</sup>There were no diaggregated data for clinical severity of the disease between the cohort of HIV‐negative participants receiving 6 months of treatment and the cohort of HIV‐positive participants receiving 9‐month ATT.<br/> <sup>d</sup>The 22 HIV‐positive children were treated with a 9‐month regimen due to a perceived slower response to treatment, as well as the 3 children with <i>M. tuberculosis</i> isoniazid‐monoresistance.<br/></p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Description of cohort studies that administered more than six months ATT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012091-tbl-0005"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Diagnosis of TBM: clinical and radiological characteristics in cohorts receiving more than six months ATT</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Previous history of TB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Known contact with TB patient</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PPD skin test positive</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Neuro‐imaging</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Abnormal chest X‐ray</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR (although 1 intracerebral tuberculoma is reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR (although 22 PTB are reported)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Done in all participants.</p> <p>5 tuberculoma,</p> <p>9 hydrocephalus, 14 arteritis, 3 spinal arachnoiditis.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50/166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50/155 had meningeal enhancement, ventricular dilatation, tuberculoma or space occupying lesion. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63/158</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CT scan in 21 participants with increased intracranial pressure:</p> <p>10 communicating hydrocephalus</p> <p>3 diffuse cerebral oedema with small lateral ventricles</p> <p>1 associated tuberculoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90/180 (≥10mm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99/180</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137/215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73/215 (≥10mm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CT scans to 68 participants with suspected hydrocephalus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111/215</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CT scan in 30 participants (14 with multiple lacunar infarct, hydrocephalus, basal meningeal enhancement). </p> <p>MRI performed in 11 participants.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Active non‐miliary TB: 214/545</p> <p>Miliary TB: 155/545</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CT scan on admission: bilateral basal ganglia infarction in all 7 cases who died before completing ATT. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Done, NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0018" title="VisudhiphanP , ChiemchanyaS . Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. The Journal of Pediatrics1989;114(5):875‐9. ">Visudhiphan 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; CT: computed tomography; MRI: magnetic resonance imaging; NR: not reported; PPD: purified protein derivative; PTB: pulmonary tuberculosis.<br/> <sup>a</sup><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> and <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> also reported cohorts of participants treated for 6 months, but did not provide disaggregated data on clinical features between both cohorts. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Diagnosis of TBM: clinical and radiological characteristics in cohorts receiving more than six months ATT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012091-tbl-0006"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Diagnosis of TBM: microbiological and other diagnostic characteristics in cohorts receiving more than six months ATT</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>CSF</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Other diagnostic methods for TB</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Diagnostic classification</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cell count, protein and glucose content</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Positive AFB smear</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Positive culture</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other tests performed in CSF</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Bacteriologically confirmed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinically diagnosed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCR: 2/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal ultrasound, sputum smear microscopy. Findings not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41/43</p> <p>23 probable,</p> <p>18 possible</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Presence of a BCG vaccine scar in 28/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82/166 had AFB smear or culture positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68/166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68/166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98/166</p> <p>14 presumptive, 84 probable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discharge of otitis media with AFB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97/180</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74/215<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88/215<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101/215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114/215</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADA in 29 cases; PCR in 2 samples</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Histology of 2 axillary lymph nodes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65/545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166/545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>187 positive cultures of samples other than CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>187/545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>352/545</p> <p>261 probable, 91 possible</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PCR for MTB in CSF 2 specimens<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Culture of gastric washings: 43/155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168/184</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0018" title="VisudhiphanP , ChiemchanyaS . Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. The Journal of Pediatrics1989;114(5):875‐9. ">Visudhiphan 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/51</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Abbreviations: ADA: adenosine deaminase activity; AFB: acid‐fast bacillus; BCG: Bacillus Calmette–Guérin; CSF: cerebrospinal fluid; DST: drug sensitivity tests; NDD: no disaggregated data; NR: not reported; MTB: <i>Mycobacterium tuberculosis</i>; PCR: polymerase chain reaction; PPD: purified protein derivative; TBM: tuberculous meningitis.<br/> <sup>a</sup>There were 30 positive cultures among 60 participants with severe forms of TB, with no disaggregated data for the 44 TBM cases.<br/> <sup>b</sup><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> and <a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> also reported cohorts of participants treated for 6 months, but did not provide disaggregated data on CSF characteristics and diagnosis classification between the cohorts.<br/> <sup>c</sup>Numbers of smear‐ and culture‐positive participants seem to be incorrectly reported.<br/> <sup>d</sup>The study authors stated that PCR was not done routinely, but did not report how many specimens were tested this way. The 2 positive PCR specimens were also culture positive. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Diagnosis of TBM: microbiological and other diagnostic characteristics in cohorts receiving more than six months ATT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012091-tbl-0007"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Findings from the Alvarez‐Uria 2012 cohort</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Duration of ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> All</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> &lt; 6 months</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> 6 months<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> &gt; 6 months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b> Participant characteristics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age (years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Previous TB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Real duration of ATT received</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In those who received 6 months or more: 8.6 months</p> <p>(259 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 months</p> <p>(34.9 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> <p>(196 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2 months</p> <p>(276 days)</p> <p>Range from 212 to 501 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b> Outcomes at the end of ATT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 (43.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Default</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (13.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (23.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1<sup>b</sup> (5%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 (43.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 (76%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b> FU in survivors (from end of ATT)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lost to FU (0 days of FU after completing ATT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/123 (5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/29 (6.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/19 (5.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/75 (5.3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of FU among survivors, mean (range)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.9 months</p> <p>687 days (9 to 1539 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.4 months</p> <p>372 days (9 to 1272 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.5 months</p> <p>915 days (66 to 1539 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 months</p> <p>750 days (30 to 1511 days)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/89 (7.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/18 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/71<sup>d</sup> (9.9%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/116 (31.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/27 (66.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/18 (16.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/71 (22.5%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131/217 (60.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111/122 (91%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/20 (20%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/75 (21.3%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>Note: we have presented the results based on complete‐case analysis.<br/> Abbreviations: ATT: antituberculous treatment; FU: follow‐up; HIV: human immunodeficiency virus; NA: not applicable; TB: tuberculosis; TBM: tuberculous meningitis.<br/> <sup>a</sup>We considered those participants treated between 180 and 209 days.<br/> <sup>b</sup>One participant had previous TB, thus the planned ATT was 8‐month regimen. The investigators classified this participant as a defaulter as he stopped ATT at 6 months.<br/> <sup>c</sup>Relapse is defined as the number of participants who have new symptoms and signs of TBM after resolution of disease and completion of ATT. None of the participants receiving less than 6‐month ATT completed their treatment. Therefore, we could not apply the term relapse to these participants. However, 5/27 participants who were defaulters and could be followed‐up, presented new symptoms and signs of TBM after stopping ATT, and were retreated.<br/> <sup>d</sup>We have presented the profile of these participants in <a href="#CD012091-tbl-0012">Table 12</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Findings from the Alvarez‐Uria 2012 cohort</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012091-tbl-0008"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Six months ATT: relapse, death, and clinical cure</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Prolonged ATT</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Losses to FU </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Length of FU after ATT, in months</b> </p> <p><b> Mean (range)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Relapse</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Death from any cause</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Death after 6 months ATT </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Clinical cure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> During ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> After ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(18 to 30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/28</p> <p>(32.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/28</p> <p>(3.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/28</p> <p>(71.4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(up to 24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/43</p> <p>(16.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/43</p> <p>(4.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/43</p> <p>(88.4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3</p> <p>(4 to 33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/29</p> <p>(13.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/29</p> <p>(86%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> <p>(16 to 45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/59</p> <p>(11.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/59</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52/59</p> <p>(88.1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/95</p> <p>(15.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/95</p> <p>(2.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82/95</p> <p>(86.3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/45</p> <p>(15.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/45</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/45</p> <p>(84.4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/159</p> <p>(5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/159</p> <p>(1.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153/159</p> <p>(96%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>458</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>28/332</b> </p> <p>(8.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0/415</b> </p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>39/381</b> </p> <p>(10.2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Range</b> </p> <p><b>4 to 45</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3/369</b> </p> <p>(0.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 death</b> </p> <p><b>2 recoveries</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>58/458</b> </p> <p>(12.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8/458</b> </p> <p>(1.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>408/458</b> </p> <p>(89.1%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; FU: follow‐up; NA: not applicable; NDD: no disaggregated data; NR: not reported.<br/> Note: we have presented these results based on complete‐case analysis.<br/> <sup>a</sup>The study authors reported 4 participants lost to follow‐up and excluded them from their analyses. However, the study authors reported that these participants received 2, 2, 3, and 4 months of ATT respectively, and correspondence via letter after a mean period of 16.5 months indicated that all had fully recovery.<br/> <sup>b</sup>Attempted length of follow‐up. No data reported on the real follow‐up of the survivors.<br/> <sup>c</sup>Follow‐up was available for at least 6 months after completion of ATT in 27/38 survivors, and for less than 6 months in 7/38. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Six months ATT: relapse, death, and clinical cure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012091-tbl-0009"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Six months ATT: default, poor adherence, treatment failure, and adverse effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Prolonged ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Losses to FU during ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Default</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Poor adherence</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Treatment failure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> All adverse effects (number of events)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Drug toxicity leading to ATT discontinuation or modification</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/29<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/29<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/29</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/95</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>458</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>28/332</b> </p> <p>(8.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0/415</b> </p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4/370</b> </p> <p>(1.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3/159</b> </p> <p>(1.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0/28</b> </p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>57</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13/197</b> </p> <p>(6.6%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; FU: follow‐up; NDD: no disaggregated data; NR: not reported.<br/> Note: we have presented these results based on complete‐case analysis.<br/> <sup>a</sup>The study authors reported that 4 participants were lost to follow‐up and excluded them from their analyses. However, the study authors reported that these participants received 2, 2, 3, and 4 months of ATT respectively, and correspondence via letter after a mean period of 16.5 months indicated that all had fully recovered. All four participants fit the definition of defaulter.<br/> <sup>b</sup>51 adverse effects were reported among the 184 participants recruited, without disaggregated data between those receiving 6 and 9 months of ATT.<br/> <sup>c</sup>ATT was discontinued in 17/184 participants, without disaggregated data between participants receiving 6 or 9 months of ATT. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Six months ATT: default, poor adherence, treatment failure, and adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012091-tbl-0010"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">More than six months ATT: relapse, death, and clinical cure</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Duration of ATT (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Prolonged ATT </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Losses to FU </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Length of FU after ATT, in months</b> </p> <p><b> Mean (range)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Relapse</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Death from any cause</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Death after 6 months ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Clinical cure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> During ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> After ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/19<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/17<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/19</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/17</p> <p>(100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/25<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/22<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/22</p> <p>(100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>7/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 10</p> <p>(6 to 24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>0/48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/37</p> <p>(13.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/37</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/30</p> <p>(83.3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 13</p> <p>(4 to 36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/35</p> <p>(5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/35</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/32</p> <p>(93.8%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 5.2</p> <p>(3.4 to 9.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/47</p> <p>(21.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/47</p> <p>(2.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/45</p> <p>(77.8%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/4</p> <p>(50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/4</p> <p>(50%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/4</p> <p>(50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/4</p> <p>(50%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 11.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individualised for all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/166 (15.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133/156</p> <p>(85.3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/28<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.8</p> <p>(12 to 29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/28</p> <p>(7.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/28</p> <p>(7.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/25</p> <p>(92%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(42 to 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64/180 (35.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/180</p> <p>(10.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119/166</p> <p>(71.7%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/215<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 death</p> <p>2 recoveries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69/215</p> <p>(32%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/215<sup>g</sup> </p> <p>(5.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137/186</p> <p>(73.7%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/42</p> <p>(16.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/42</p> <p>(83%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40/336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 53.4</p> <p>(IQR 47.4 to 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/296<sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 recoveries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>249/545 (45.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>336/535</p> <p>(62.8%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>HIV‐positive and isoniazid‐resistant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/25</p> <p>(24%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/25</p> <p>(20%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/25</p> <p>(96%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0018" title="VisudhiphanP , ChiemchanyaS . Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. The Journal of Pediatrics1989;114(5):875‐9. ">Visudhiphan 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(18 to 84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/51</p> <p>(5.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/51</p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/47</p> <p>(93.6%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 to 16</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1423</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32/472 and 166 individualized ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>87/1423</b> </p> <p>(6.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>56/985</b> </p> <p>(5.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Range</b> </p> <p><b>6 to 84</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7/915</b> </p> <p>(0.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 death</b> </p> <p><b>6 recoveries</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>447/1423</b> </p> <p>(31.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>39/662</b> </p> <p>(5.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>984/1336</b> </p> <p>(73.7%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="12"> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; FU: follow‐up; HIV: human immunodeficiency virus; IQR: interquartile range; NA: not applicable; NDD: no disaggregated data; NR: not reported.<br/> Note: we have presented these results based on complete‐case analysis.<br/> <sup>a</sup>There were 5 participants (2 in the 9‐month group, 3 in the 12‐month group) lost to follow‐up at the end of the 5 years follow‐up. No results were reported for these 5 participants, and it is unclear when they left the trial and what their outcomes were.<br/> <sup>b</sup>Attempted length of follow‐up. No data reported on the real follow‐up of the survivors.<br/> <sup>c</sup>Data could not be disaggregated by time until death. There were 7 deaths in the 6‐month group, 2 in the 9‐month group, and 2 in the 12‐month group; the study authors stated that over 90% of deaths occurred within the first 3 months of treatment in this study.<br/> <sup>d</sup>There were at least 3 deaths after six months of ATT. Indeed, three participants died in the second year from the start of ATT, due to nasopharyngeal carcinoma, acquired immune deficiency syndrome and chronic obstructive pulmonary disease. There were no disaggregated data among the deaths occuring within the first 12 months to report those occuring between the sixth and twelfth months from the start of ATT.<br/> <sup>e</sup>Three participants with poor compliance dropped out during the early stage of ATT and could not be followed‐up. One participant developed erythema multiform and had treatment suspended, then restarted with RHS. Another participant completed ATT but was lost to follow‐up afterwards.<br/> <sup>f</sup>Ten out of these 29 participants received modified ATT regimens with unknown reason, and the study authors excluded them from analysis.<br/> <sup>g</sup>Ten participants discharged against medical advice died.<br/> <sup>h</sup>143 participants received altered ATT regimen due to adverse events. It is unknown whether these participants received prolonged ATT.<br/> <sup>i</sup>These 3 participants were re‐treated for TB. It is unclear whether they were re‐treated because of TBM relapse or because of presenting another form of TB.<br/> <sup>j</sup>There were 50 deaths reported among the 296 survivors who completed the 9‐month treatment. We do not know if there were additional number of death between the sixth and ninth month of ATT, due to a lack of data reporting. The study authors could not determine how many of these deaths could be attributed to relapse. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">More than six months ATT: relapse, death, and clinical cure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012091-tbl-0011"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">More than six months ATT: default, poor adherence, treatment failure, and adverse effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Duration of ATT (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Number of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Prolonged ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Losses to FU during ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Default</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Poor adherence</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Treatment failure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> All adverse effects (number of events)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Drug toxicity leading to ATT discontinuation or modification</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/19<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/30<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12/62</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/45<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 11.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Individualised for all</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/156</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/28<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/174</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/215<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/205</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89/535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143/535</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> <p>HIV‐pos and H‐resistant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD<sup>i</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0018" title="VisudhiphanP , ChiemchanyaS . Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. The Journal of Pediatrics1989;114(5):875‐9. ">Visudhiphan 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 to 16</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1423</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32/472 and 166 individualized ATT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>87/1423</b> </p> <p>(6.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8/355</b> </p> <p>(2.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0/181</b> </p> <p>(0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>95/681</b> </p> <p>(14.0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>567</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>216/1299</b> </p> <p>(16.6%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; FU: follow‐up; H: isoniazid; HIV: human immunodeficiency virus; mo: months; NDD: no disaggregated data; NR: not reported.<br/> Note: we have presented these results based on complete‐case analysis.<br/> <sup>a</sup>There were 5 participants (2 in the 9‐month group, 3 in the 12‐month group) lost to follow‐up at the end of the 5 years follow‐up. No results were reported for these five participants, and it is unclear when they left the trial and what their outcomes were.<br/> <sup>b</sup>This study described 1 participant in the 8‐month ATT group as having treatment modified due to "inadequate clinical response", and 1 participant in the 12‐ to 16‐month ATT group as dying in the fifth month of treatment due to "therapeutic failure".<br/> <sup>c</sup>Four participants developed treatment failure, 3 during the fourth month of ATT, and 1 during the ninth month (who had concurrent pulmonary TB with proven isoniazid resistance). Three of these 4 participants died.<br/> <sup>d</sup>Three participants with poor compliance dropped out during the early stage of ATT and could not be followed‐up. One participant developed erythema multiform and had treatment suspended, then restarted with RHS. Another participant completed ATT but was lost to follow‐up afterwards.<br/> <sup>e</sup>Ten out of these 29 participants received modified ATT regimens with unknown reason, and the study authors excluded them from analysis.<br/> <sup>f</sup>The study authors stated that out of the 42 participants, 35 completed ATT, and 7 died. It is very likely that there was no defaulters, although this outcome was not clearly stated.<br/> <sup>g</sup>143 participants received altered ATT regimen due to adverse events. It is unknown whether these participants received prolonged ATT.<br/> <sup>h</sup>51 adverse effects are reported among the 184 participants, without disaggregated data between participants receiving 6 or 9 months of ATT.<br/> <sup>i</sup>ATT was discontinued in 17/184 participants, without disaggregated data between participants receiving 6 or 9 months of ATT. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">More than six months ATT: default, poor adherence, treatment failure, and adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012091-tbl-0012"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Profile of participants who relapsed after completing ATT</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Gender, age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Duration of ATT received (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Time between end of ATT and relapse</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Six months ATT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Female, 34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease severity: stage III when first diagnosed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease severity: stage I at relapse</p> <p>It is unclear whether or not this participant missed doses in the continuation phase of treatment, but the study authors reported that missed doses were made up in all participants. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Female, 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disease severity: stage I when first diagnosed, and stage II at relapse</p> <p>During the first course of ATT, Eth was stopped and the dosage of H and R halved to 10 mg/kg and Z halved to 20 mg/kg due to poor appetite and nausea after 3 months of treatment. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>More than six months ATT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, adult</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Child</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive CSF culture, fully sensitive on DST at initial diagnosis and relapse.</p> <p>Mild sequelae at the end of first course of ATT. Treated with ‘intensive therapy’ for 9 months, died 10 months after completing the second ATT regimen despite having normal CSF analysis and negative CSF cultures. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Child</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive CSF culture, fully sensitive on DST at initial diagnosis and relapse.</p> <p>Mild sequelae at the end of first course of ATT.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Child</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abnormal CSF and positive CSF culture, resistant to H and S on DST at initial diagnosis and relapse. </p> <p>Moderate sequelae at the end of first course of ATT.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>At five‐year follow‐up, these three participants self‐reported re‐treatment for TB. It is unclear whether this was for TBM or another form of TB. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adult</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Additional cohort</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD012091-bbs2-0002" title="Alvarez‐UriaG , NaikPK , PakamR , BachuL , MiddeM . Natural history and factors associated with early and delayed mortality in HIV‐infected patients treated of tuberculosis under directly observed treatment short‐course strategy: a prospective cohort study in India. Interdisciplinary Perspectives on Infectious Diseases2012;2012:502012. [DOI: 10.1155/2012/502012] ">Alvarez‐Uria 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, 32, HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This participant had previous TB</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, 65, HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, 31, HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This participant was cure after completing ATT for relapse. However, he died 12 months after completing the second ATT regimen. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, 32, HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This participant had previous TB</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, 32, HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This participant had previous TB</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, 45, HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Male, 13, HIV‐positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recovery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; CSF: cerebrospinal fluid; DST: drug sensitivity tests; Eth: ethinamide; H: isoniazid; HIV: human immunodeficiency virus; R: rifampicin; TB: tuberculosis; Z: pyrazinamide. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Profile of participants who relapsed after completing ATT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012091-tbl-0013"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Causes of deaths after six months ATT</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Length of treatment (months)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Deaths after 6 months ATT</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b> Number of these deaths attributed to:</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Relapse</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Complications of TBM<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Non TB causes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Unknown</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b> Six months ATT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>More than six months ATT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>4 (HIV infection or post‐TBM complications)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.53 (mean)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; HIV: human immunodeficiency virus; mo: months; TB: tuberculosis; TBM: tuberculous meningitis. </p> <p><sup>a</sup>Death due to TBM complications can occur at any point in the course of treatment regardless of treatment duration, even after microbiological cure has been achieved. The complications leading to deaths reported in the included studies were all related to severe neurological sequelae.<br/> <sup>b</sup>There were 50 deaths reported among the 296 survivors who completed the nine‐month treatment. We do not know if there were additional number of death between the sixth and ninth month of ATT, due to a lack of data reporting. Authors could not determine how many of these deaths could be attributed to relapse.<br/> <sup>c</sup>Three participants died in the second year from the start of ATT, due to nasopharyngeal carcinoma, acquired immune deficiency syndrome, and chronic obstructive pulmonary disease. There were no disaggregated data among the deaths occuring within the first 12 months to report those occuring between the sixth and twelfth months from the start of ATT. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Causes of deaths after six months ATT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012091-tbl-0014"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study ID</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Number of adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Description of adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Related to ATT (events)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Leading to ATT discontinuation (participants)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Six months ATT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0001" title="AlarcónF , EscalanteL , PérezY , BandaH , ChacónG , DueñasG . Tuberculous meningitis. Short course of chemotherapy. Archives of Neurology1990;47(12):1313‐7. ">Alarcón 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0021"> <li> <p>Elevation in ALT/AST/alkaline phosphatase/bilirubin: 15, leading to discontinuation of treatment with H/R and substitution with S for 3 to 7 days in 4 participants. </p> </li> <li> <p>Hyperuricaemia leading to 3‐day suspension of Z in 2 participants.</p> </li> <li> <p>Gastrointestinal symptoms 3 participants.</p> </li> <li> <p>Arthralgia 2 participants.</p> </li> <li> <p>Dizziness with nystagmus 1 participant.</p> </li> <li> <p>Rash 1 participant.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0004" title="BiddulphJ . Short course chemotherapy for childhood tuberculosis. Paediatric Infectious Diseases Journal1990;9(11):794‐801. ">Biddulph 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NDD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/639 TB cases had problems with the drug prescribed, but NDD for TBM.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0005" title="ChotmongkolV . Treatment of tuberculous meningitis with 6‐month course of chemotherapy. Southeast Asian Journal of Tropical Medicine and Public Health1991;22(3):372‐4. ">Chotmongkol 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0022"> <li> <p>1 severe hepatitis due to H. ATT was continued with R and E for 18 months with full recovery. </p> </li> <li> <p>No other adverse events reported.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0006" title="ChotmongkolV , JitpimolmardS , ThavornpitakY . Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand [Chotmaihet Thangphaet]1996;79(2):83‐90. ">Chotmongkol 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0023"> <li> <p>Gastrointestinal bleeding or hyperglycemia was not observed as complications of prednisolone therapy. </p> </li> <li> <p>Adverse events were assessed and recorded; but results not reported.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0008" title="DonaldPR , SchoemanJF , vanZylLE , deVilliersJN , PretoriusM , SpringerP . Intensive short course chemotherapy in the management of tuberculous meningitis. International Journal of Tuberculosis and Lung Disease1998;2(9):704‐11. ">Donald 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0024"> <li> <p>Nausea and vomiting leading to stopping of Eth and reduction of RH doses. This case relapsed and was successfully re‐treated with HRZEth at full doses. </p> </li> <li> <p>Hepatotoxicity:</p> <ul id="CD012091-list-0025"> <li> <p>10 mild elevation of bilirubin leading to substitution of HRZEth with SE in 5 children, who were then re‐started on HRZEth when liver function normalised in 2 to 3 weeks; </p> </li> <li> <p>13 mild and transient elevation of ALT/AST, without treatment interruption.</p> </li> </ul> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Six and more than six months ATT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012091-bbs2-0010" title="JacobsRF , SunakornP , ChotpitayasunonahT , PopeS , KelleherK . Intensive short course chemotherapy for tuberculous meningitis. The Pediatric Infectious Disease Journal1992;11(3):194‐8. ">Jacobs 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0017" title="vanToornR , SchaafHS , LaubscherJA , vanElslandSL , DonaldPR , SchoemanJF . Short intensified treatment in children with drug‐susceptible tuberculous meningitis. The Pediatric Infectious Disease Journal2014;33(3):248‐52. [DOI: 10.1097/INF.0000000000000065] ">van Toorn 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0026"> <li> <p>Anti‐TB drug‐induced hepatotoxicity (ADIH):</p> <ul id="CD012091-list-0027"> <li> <p>Grade 1 (mild) ALT 51 to 125 U/L: 18/184;</p> </li> <li> <p>Grade 2 (mild) ALT 126 to 250 U/L: 6/184; ATT changed to liver‐friendly regimens;</p> </li> <li> <p>Grade 3 (moderate) ALT 251 to 500 U/L: 6/184; ATT changed to liver‐friendly regimens;</p> </li> <li> <p>Grade 4 (severe) ALT &gt; 500 U/L: 2/184; ATT changed to liver‐friendly regimens.</p> </li> </ul> </li> </ul> </p> <p>In all ADIH cases from grade 2 severity, change to liver‐friendly regimens resulted in normalization of liver enzymes (medium duration 7 days, range 3 to 16 days) and the original regimen was restarted (stepwise) without recurrence. </p> <p> <ul id="CD012091-list-0028"> <li> <p>Significant nausea and vomiting: 19/184</p> </li> </ul> </p> <p>Eth was substituted with E in 3 cases, solving the problem. In the remaining 16 cases, administration of Eth at night solved the problem. </p> <p>Of these 19 participants, 8 had drug‐induced hepatotoxicity and 11 had normal liver function. In these 11 either substituting Eth for E or giving Eth at night resolved the nausea and vomiting. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>More than six months ATT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0003" title="AnastasatuC , AnastasatuO , MurgociG , DobreM . [The late results of intensive chemotherapy (9 months) in severe forms of tuberculosis in children]. Pneumoftiziologia1993;42(4):9‐12. ">Anastasatu 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD012091-bbs2-0007" title="DoğanayM , ÇalanguS , TurgutH , BakirM , AygenB . Treatment of tuberculous meningitis in Turkey. Scandinavian Journal of Infectious Diseases1989;27(2):135‐8. ">Doğanay 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>12/72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD012091-list-0029"> <li> <p>2 nausea and vomiting.</p> </li> <li> <p>10 toxic hepatitis with a moderate increase in hepatic enzyme levels. HR were discontinued in these cases for a short time (3 to 5 days) and after recovery, reinstituted. </p> </li> <li> <p>2 hearing loss. S was stopped.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0009" title="IypeT , PillaiAK , CherianA , NujumZT , PushpaC , DaeD , et al. Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime. Annals of Indian Academy of Neurology2014;17(3):281‐6. [DOI: 10.4103/0972‐2327.138496] ">Iype 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0030"> <li> <p>8 paradoxical reactions (increased size of tuberculoma or development of new tuberculoma, 2 died) </p> </li> <li> <p>4 hepatitis: 1 at the end of 1<sup>st</sup> month; 2 at 4 months; 1 at 7 months. One case of hepatitis led to discontinuation of ATT at 124 days. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0011" title="LauKK , YuIT , ChanAC , WongLK , TamCM , ShengB , et al. A registry of tuberculous meningitis in Hong Kong. International Journal of Tuberculosis and Lung Disease2005;9(12):1391‐7. ">Lau 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin rash, hearing difficulty, impaired liver function with elevated ALT, and blurring of vision. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0012" title="PhuapraditP , VejjajivaA . Treatment of tuberculous meningitis: role of short‐course chemotherapy. The Quarterly Journal of Medicine1987;62(239):249‐58. ">Phuapradit 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0031"> <li> <p>6 participants with 2 to 3‐fold elevation of ALT/AST ± alkaline phosphatase level (no discontinuation of ATT) during the early weeks of treatment. </p> </li> <li> <p>14 participants with asymptomatic hyperuricemia (90 to 140 mg/L) during the first 2 months of ATT when Z was given, 8 received probenecid. </p> </li> <li> <p>1 erythema multiforme from Z. All drugs were discontinued. After rashes healed, ATT was continued with HRS with full recovery. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0013" title="RamachandranP , DuraipandianM , NagarajanM , PrabhakarR , RamakrishnanCV , TripathySP . Three chemotherapy studies of tuberculous meningitis in children. Tubercle1986;67(1):17‐29. RamachandranP , DuraipandianM , ReethaAM , MahalakshmiSM , PrabhakarR . Long‐term status of children treated for tuberculous meningitis in south India. Tubercle1989;70(4):235‐9. ">Ramachandran 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (36*)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (36*)/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0032"> <li> <p>4 cases according to the 1989 publication (*3 cases according to the 1986 publication) with ocular complications: ethambutol was discontinued and PAS substituted, even though it was clear that the problem was unrelated to drugs. </p> </li> <li> <p>30 jaundice: R (first study) or both RZ (second and third studies) were discontinued while the other drugs were continued. </p> </li> <li> <p>2 skin reactions: R was stopped in 1 participant and the participant recovered completely; all anti‐tuberculosis drugs were withheld for 1 week in the other participant and the participant recovered fully. The treatment was resumed uneventfully. </p> </li> <li> <p>1 arthralgia: Z was stopped and the swelling diminished during the next 3 weeks. He could not be followed up further as he died of TBM. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0014" title="RamachandranP , DuraipandianM , ReethaAM . A 5 year follow‐up study of children treated for tuberculous meningitis with short course chemotherapy. The Indian Journal of Tuberculosis1997;44:125‐7. RamachandranP , KripasankarAS , ReethaAM , MahalakshmiSM , PrabhakarR . Short course chemotherapy study in tuberculous meningitis in children. The Indian Journal of Tuberculosis1997;44:195‐200. ">Ramachandran 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 participants developed jaundice with abnormal liver function tests</p> <p>5 participants had an increase in hepatic enzymes levels without clinical jaundice</p> <p>For these 15 participants: R and Z were terminated and other drugs were continued.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0015" title="SharmaSR , LynrahKG , SharmaN , LyngdohM . Directly observed treatment, short course in tuberculous meningitis: Indian perspective. Annals of Indian Academy of Neurology2013;16(1):82‐4. [DOI: 10.4103/0972‐2327.107717] ">Sharma 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0033"> <li> <p>1 drug‐induced hepatitis causing death.</p> </li> <li> <p>2 participants with clinical jaundice and persistent vomiting who were converted to daily regimen. </p> </li> <li> <p>No other adverse events reported.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0016" title="ThwaitesGE , NguyenDB , NguyenHD , HoangTQ , DoTT , NguyenTC , et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. The New England of Journal Medicine2004;351(17):1741‐51. TörökME , NguyenDB , TranTH , NguyenTB , ThwaitesGE , HoangTQ , et al. Dexamethasone and long‐term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One2011;6(12):e27821. [DOI: 10.1371/journal.pone.0027821] ">Török 2011a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155/545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>329 non‐severe; 71 severe</p> <p> <ul id="CD012091-list-0034"> <li> <p>Subclinical hepatitis: 92 non‐severe; 0 severe.</p> </li> <li> <p>Clinical hepatitis: 9 non‐severe; 8 severe.</p> </li> <li> <p>Gastrointestinal bleeding: 10 non‐severe; 5 severe.</p> </li> <li> <p>Bacterial sepsis: 12 non‐severe; 7 severe.</p> </li> <li> <p>Septic shock: 0 non‐severe; 3 severe.</p> </li> <li> <p>Brain herniation syndrome: 0 non‐severe; 5 severe.</p> </li> <li> <p>Decrease in visual acuity: 16 non‐severe; 14 severe.</p> </li> <li> <p>Hyponatremia: 11 non‐severe; 7 severe.</p> </li> <li> <p>Hyperglycaemia: 5 non‐severe; 0 severe.</p> </li> <li> <p>Hypertension: 5 non‐severe; 0 severe.</p> </li> <li> <p>Vertigo: 39 non‐severe; 0 severe.</p> </li> <li> <p>Deafness: 8 non‐severe; 6 severe.</p> </li> <li> <p>Cushing’s features: 12 non‐severe; 0 severe.</p> </li> <li> <p>Pruritus: 12 non‐severe; 0 severe.</p> </li> <li> <p>Polyarthralgia: 5 non‐severe; 0 severe.</p> </li> <li> <p>Streptomycin reaction: 4 non‐severe; 0 severe.</p> </li> <li> <p>Rifampin flu: 7 non‐severe; 0 severe.</p> </li> <li> <p>Rash: 13 non‐severe; 1 severe.</p> </li> <li> <p>Other (other events that were reported fewer than 4 times): 76 non‐severe; 15 severe.</p> </li> </ul> </p> <p>ATT was stopped or modified in 143 participants.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012091-bbs2-0018" title="VisudhiphanP , ChiemchanyaS . Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. The Journal of Pediatrics1989;114(5):875‐9. ">Visudhiphan 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD012091-list-0035"> <li> <p>4 participants: elevation of serum AST/ALT levels à rifampicin dose decreased to 10 mg/kg/day in 3 participants, and to 8 mg/kg/day in the 4th participant. </p> </li> <li> <p>8 participants with mild gastrointestinal disturbances.</p> </li> </ul> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Abbreviations: ALT: alanine transaminase; AST: aspartate transaminase; ATT: antituberculous treatment, E: ethambutol; Eth: ethionamide; H: isoniazid; HIV: human immunodeficiency virus; NDD: no disaggregated data; NR: not reported; R: rifampicin; Z: pyrazinamide </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012091.pub2/full#CD012091-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012091.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012091-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012091-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD012091-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD012091-note-0001">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012091-note-0022">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012091\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012091\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012091\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012091\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012091\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012091\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012091\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012091\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012091\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012091\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012091.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012091.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012091.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012091.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012091.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714855730"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012091.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714855733"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012091.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d78dc08d9937d',t:'MTc0MDcxNDg1Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 